CARES Act

To provide emergency assistance and health care response for individuals, families, and businesses affected by the 2020 coronavirus pandemic. 1. Short title This Act may be cited as the Coronavirus Aid, Relief, and Economic Security Act CARES Act 2. Table of contents The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents. DIVISION A—Small business interruption loans Sec. 1101. Definitions. Sec. 1102. 7 (a) Sec. 1103. Entrepreneurial development. Sec. 1104. Waiver of matching funds requirement under the women’s business center program. Sec. 1105. Loan forgiveness. Sec. 1106. Direct appropriations. Sec. 1107. Minority business development agency. Sec. 1108. Waiver of prepayment penalty. Sec. 1109. United States Treasury Program Management Authority. DIVISION B—Relief for individuals, families, and businesses TITLE I—Rebates and other individual provisions Sec. 2101. 2020 recovery rebates for individuals. Sec. 2102. Delay of certain deadlines. Sec. 2103. Special rules for use of retirement funds. Sec. 2104. Allowance of partial above the line deduction for charitable contributions. Sec. 2105. Modification of limitations on charitable contributions during 2020. TITLE II—Business provisions Sec. 2201. Delay of estimated tax payments for corporations. Sec. 2202. Delay of payment of employer payroll taxes. Sec. 2203. Modifications for net operating losses. Sec. 2204. Modification of limitation on losses for taxpayers other than corporations. Sec. 2205. Modification of credit for prior year minimum tax liability of corporations. Sec. 2206. Modification of limitation on business interest. Sec. 2207. Technical amendments regarding qualified improvement property. Sec. 2208. Installments not to prevent credit or refund of overpayments or increase estimated taxes. Sec. 2209. Restoration of limitation on downward attribution of stock ownership in applying constructive ownership rules. DIVISION C—Assistance to severely distressed sectors of the United States economy TITLE I—Economic Stabilization Sec. 3101. Short title. Sec. 3102. Emergency relief through loans and loan guarantees. Sec. 3103. Limitation on certain employee compensation. Sec. 3104. Continuation of certain air service. Sec. 3105. Reports. Sec. 3106. Coordination with Secretary of Transportation. Sec. 3107. Definitions. Sec. 3108. Rule of construction. TITLE II—Aviation excise taxes Sec. 3201. Suspension of certain aviation excise taxes. DIVISION D—Health care response TITLE I—Health provisions Subtitle A—Addressing supply shortages PART I—Moving the strategic national stockpile to ASPR Sec. 4101. Moving the strategic national stockpile to ASPR. PART II—Medical product supplies Sec. 4111. National Academies report on America’s medical product supply chain security. Sec. 4112. Requiring the strategic national stockpile to include certain types of medical supplies. Sec. 4113. Treatment of respiratory protective devices as covered countermeasures. PART III—Mitigating emergency drug shortages Sec. 4121. Prioritize reviews of drug applications; incentives. Sec. 4122. Additional manufacturer reporting requirements in response to drug shortages. Sec. 4123. GAO report on intra-agency coordination. Sec. 4124. Report. Sec. 4125. Safe harbor provision. PART IV—Preventing essential medical device shortages Sec. 4131. Discontinuance or interruption in the production of medical devices. Sec. 4132. GAO report on intra-agency coordination. PART V—Emergency use of laboratory developed tests Sec. 4141. Emergency use of laboratory developed tests. Subtitle B—Access to health care for COVID-19 patients PART I—Coverage of testing and preventive services Sec. 4201. Coverage of diagnostic testing for COVID-19. Sec. 4202. Pricing of diagnostic testing. Sec. 4203. Rapid coverage of preventive services and vaccines for coronavirus. PART II—Support for health care providers Sec. 4211. Supplemental awards for health centers. Sec. 4212. Allowing permanent direct hire of NDMS health care professionals. Sec. 4213. Telehealth network and telehealth resource centers grant programs. Sec. 4214. Rural health care services outreach, rural health network development, and small health care provider quality improvement grant programs. Sec. 4215. United States Public Health Service Modernization. Sec. 4216. Limitation on liability for volunteer health care professionals during covid-19 emergency response. PART III—Miscellaneous provisions Sec. 4221. Confidentiality and disclosure of records relating to substance use disorder. Sec. 4222. Nutrition services. Sec. 4223. Guidance on protected health information. Sec. 4224. Reauthorization of healthy start program. Subtitle C—Innovation Sec. 4301. Removing the cap on OTA. Sec. 4302. Extending the priority review program for agents that present national security threats. Sec. 4303. Priority zoonotic animal drugs. Subtitle D—Finance Committee Sec. 4401. Exemption for telehealth services. Sec. 4402. Inclusion of certain over-the-counter medical products as qualified medical expenses. Sec. 4403. Treatment of direct primary care service arrangements. Sec. 4404. Increasing Medicare telehealth flexibilities during emergency period. Sec. 4405. Enhancing Medicare telehealth services for Federally qualified health centers and rural health clinics during emergency period. Sec. 4406. Temporary waiver of requirement for face-to-face visits between home dialysis patients and physicians. Sec. 4407. Improving care planning for Medicare home health services. Sec. 4408. Adjustment of sequestration. Sec. 4409. Medicare hospital inpatient prospective payment system add-on payment for covid–19 patients during emergency period. Sec. 4410. Revising payment rates for durable medical equipment under the Medicare program through duration of emergency period. Sec. 4411. Providing home and community-based services in acute care hospitals. Sec. 4412. Treatment of technology-enabled collaborative learning and capacity building models as medical assistance. Sec. 4413. Encouraging the development and use of DISARM antimicrobial drugs. Sec. 4414. Novel medical products. TITLE II—Education provisions Sec. 4501. Short title. Sec. 4502. Definitions. Sec. 4503. Campus-based aid waivers. Sec. 4504. Use of supplemental educational opportunity grants for emergency aid. Sec. 4505. Federal work-study during a qualifying emergency. Sec. 4506. Adjustment of subsidized loan usage limits. Sec. 4507. Exclusion from Federal Pell Grant duration limit. Sec. 4508. Institutional refunds and Federal student loan flexibility. Sec. 4509. Satisfactory progress. Sec. 4510. Continuing education at affected foreign institutions. Sec. 4511. National emergency educational waivers. Sec. 4512. HBCU Capital financing. Sec. 4513. Temporary relief for federal student loan borrowers. Sec. 4514. Provisions related to the Corporation for National and Community Service. Sec. 4515. Workforce response activities. Sec. 4516. Technical amendments. TITLE III—Labor provisions Sec. 4601. Limitation on paid leave. Sec. 4602. Emergency Paid Sick Leave Act Limitation. Sec. 4603. Regulatory Authorities under the Emergency Paid Sick Leave Act. Sec. 4604. Unemployment insurance. Sec. 4605. OMB Waiver of Paid Family and Paid Sick Leave. Sec. 4606. Paid leave for rehired employees. Sec. 4607. Advance refunding of credits. DIVISION E—Temporary Permit Use to Guarantee Money Market Mutual Funds Sec. 5001. Non-applicability of restrictions on ESF during national emergency. DIVISION F—Budgetary provisions Sec. 6001. Emergency designation. A Small business interruption loans 1101. Definitions In this division— (1) the terms Administration Administrator (2) the term small business concern 15 U.S.C. 632 1102. 7 (a) (a) Definition of covered period In this section, the term covered period (b) Increased eligibility for certain small businesses and organizations (1) In general During the covered period, any business concern, private nonprofit organization, or public nonprofit organization which employs not more than 500 employees shall be eligible to receive a loan made under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (2) Exclusion of nonprofits receiving Medicaid expenditures Paragraph (1) shall not apply to a nonprofit entity eligible for payment for items or services furnished under a State plan under title XIX of the Social Security Act ( 42 U.S.C. 1396 (c) Maximum loan amount During the covered period, with respect to any loan guaranteed under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (1) the product obtained by multiplying— (A) the average total monthly payments by the applicant for payroll, mortgage payments, rent payments, and payments on any other debt obligations incurred during the 1 year period before the date on which the loan is made, except that, in the case of an applicant that is seasonal employer, as determined by the Administrator, the average total monthly payments for payroll shall be for the period beginning March 1, 2019 and ending June 30, 2019; by (B) 4; or (2) $10,000,000. (d) Allowable uses of program loans (1) In general During the covered period, a recipient of a loan made under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (A) payroll support, including paid sick, medical, or family leave, and costs related to the continuation of group health care benefits during those periods of leave; (B) employee salaries; (C) mortgage payments; (D) rent (including rent under a lease agreement); (E) utilities; and (F) any other debt obligations that were incurred before the covered period. (2) Delegated authority (A) In general For purposes of making loans for the purposes described in paragraph (1), a lender under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (B) Considerations In evaluating the eligibility of a borrower for a loan under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (i) was in operation on March 1, 2020; and (ii) had employees for whom the borrower paid salaries and payroll taxes. (3) Limitation A borrower that receives assistance under section 7(b)(2) of the Small Business Act ( 15 U.S.C. 636(b)(2) (e) Fee waiver for 7(a) loans During the covered period, with respect to each loan guaranteed under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (1) in lieu of the fee otherwise applicable under section 7(a)(23)(A) of the Small Business Act ( 15 U.S.C. 636(a)(23)(A) (2) for which the application is approved on or after the date of enactment of this Act, the Administrator shall, in lieu of the fee otherwise applicable under section 7(a)(18)(A) of the Small Business Act ( 15 U.S.C. 636(a)(18)(A) (f) Guarantee amount for 7(a) loans (1) In general Section 7(a)(2)(A) of the Small Business Act ( 15 U.S.C. 636(a)(2)(A) equal to— equal to 100 percent of the balance of the financing outstanding at the time of disbursement of the loan. (2) Prospective repeal Effective on January 1, 2021, section 7(a)(2)(A) of the Small Business Act ( 15 U.S.C. 636(a)(2)(A) equal to 100 percent of the balance of financing outstanding at the time of disbursement of the loan equal to— (i) 75 percent of the balance of the financing outstanding at the time of disbursement of the loan, if such balance exceeds $150,000; or (ii) 85 percent of the balance of the financing outstanding at the time of disbursement of the loan, if such balance is less than or equal to $150,000. . (g) Deferment of 7(a) Loans (1) Definitions (A) Eligible borrower The term eligible borrower (i) a small business concern; or (ii) an organization made eligible by subsection (b) of this section for a loan under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (B) Impacted borrower (i) In general In this subsection, the term impacted borrower (I) is in operation on March 1, 2020; and (II) has an application for a loan made under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (ii) Presumption For purposes of this subsection, an impacted borrower is presumed to have been adversely impacted by COVID–19. (2) Deferral During the covered period, the Administrator shall— (A) consider each eligible borrower that applies for a loan under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (B) require lenders under such section 7(a) to provide complete payment deferment relief for impacted borrowers with loans guaranteed under such section 7(a) for a period of not more than 1 year. (3) Secondary market During the covered period, with respect to a loan made under 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (4) Guidance Not later than 30 days after the date of enactment of this Act, the Administrator shall provide guidance to lenders under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (h) Commitments for 7(a) loans During the covered period— (1) there shall be no limitation on the commitments for general business loans authorized under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (2) the amount authorized for commitments for such loans under the heading business loans program account Small business administration Public Law 116–93 (i) Express loans (1) In general Section 7(a)(31)(D) of the Small Business Act ( 15 U.S.C. 636(a)(31)(D) $350,000 $1,000,000 (2) Prospective repeal Effective on January 1, 2021, section 7(a)(31)(D) of the Small Business Act ( 15 U.S.C. 636(a)(31)(D) $1,000,000 $350,000 1103. Entrepreneurial development (a) Definitions In this section— (1) the term covered small business concern (2) the term resource partner (A) a small business development center; and (B) a women's business center; (3) the term small business development center 15 U.S.C. 632 (4) the term substantially affected by COVID–19 (A) supply chain disruptions, including changes in— (i) quantity and lead time, including the number of shipments of components and delays in shipments; (ii) quality, including shortages in supply for quality control reasons; and (iii) technology, including a compromised payment network; (B) staffing challenges; (C) a decrease in sales or customers; or (D) shuttered businesses; and (5) the term women's business center 15 U.S.C. 656 (b) Education, training, and advising grants (1) In general The Administration may provide financial assistance in the form of grants to resource partners to provide education, training, and advising to covered small business concerns. (2) Use of funds Grants under this subsection shall be used for the education, training, and advising of covered small business concerns and their employees on— (A) accessing and applying for resources provided by the Administration and other Federal resources relating to access to capital and business resiliency; (B) the hazards and prevention of the transmission and communication of COVID–19 and other communicable diseases; (C) the potential effects of COVID–19 on the supply chains, distribution, and sale of products of covered small business concerns and the mitigation of those effects; (D) the management and practice of telework to reduce possible transmission of COVID–19; (E) the management and practice of remote customer service by electronic or other means; (F) the risks of and mitigation of cyber threats in remote customer service or telework practices; (G) the mitigation of the effects of reduced travel or outside activities on covered small business concerns during COVID–19 or similar occurrences; and (H) any other relevant business practices necessary to mitigate the economic effects of COVID–19 or similar occurrences. (3) Grant determination (A) Small business development centers The Administration shall award 80 percent of funds authorized to carry out this subsection to small business development centers, which shall be awarded pursuant to a formula jointly developed, negotiated, and agreed upon, with full participation of both parties, between the association formed under section 21(a)(3)(A) of the Small Business Act ( 15 U.S.C. 648(a)(3)(A) (B) Women's business centers The Administration shall award 20 percent of funds authorized to carry out this subsection to women's business centers, which shall be awarded pursuant to a process established by the Administration in consultation with recipients of assistance. (C) No matching funds required Matching funds shall not be required for any grant under this subsection. (4) Goals and metrics (A) In general Goals and metrics for the funds made available under this subsection shall be jointly developed, negotiated, and agreed upon, with full participation of both parties, between the resource partners and the Administrator, which shall— (i) take into consideration the extent of the circumstances relating to the spread of COVID–19, or similar occurrences, that affect covered small business concerns located in the areas covered by the resource partner, particularly in rural areas or economically distressed areas; (ii) generally follow the use of funds outlined in paragraph (2), but shall not restrict the activities of resource partners in responding to unique situations; and (iii) encourage resource partners to develop and provide services to covered small business concerns. (B) Public availability The Administrator shall make publicly available the methodology by which the Administrator and resource partners jointly develop the metrics and goals described in subparagraph (A). (c) Resource partner association grants (1) In general The Administrator may provide grants to an association or associations representing resource partners to establish a centralized hub for COVID–19 information, which shall include— (A) an online platform that consolidates resources and information available across multiple Federal agencies for small business concerns related to COVID–19; and (B) a training program to educate resource partner counselors on the resources and information described in subparagraph (A). (2) Goals and metrics Goals and metrics for the funds made available under this subsection shall be jointly developed, negotiated, and agreed upon, with full participation of both parties, between the association or associations receiving a grant under this subsection and the Administrator. (d) Report Not later than 6 months after the date of enactment of this Act, and annually thereafter, the Administrator shall submit to the Committee on Small Business and Entrepreneurship of the Senate and the Committee on Small Business of the House of Representatives a report— (1) that describes, with respect to the initial year covered by the report— (A) the programs and services developed and provided by the Administration and resource partners under subsection (b); (B) the initial efforts to provide those services under subsection (b); and (C) the online platform and training developed and provided by the Administration and the association or associations under subsection (c); and (2) that describes, with respect to the subsequent years covered by the report— (A) with respect to the grant program under subsection (b)— (i) the efforts of the Administrator and resource partners to develop services to assist covered small business concerns; (ii) the challenges faced by owners of covered small business concerns in accessing services provided by the Administration and resource partners; (iii) the number of unique covered small business concerns that were served by the Administration and resource partners; and (iv) other relevant outcome performance data with respect to covered small business concerns, including the number of employees affected, the effect on sales, the disruptions of supply chains, and the efforts made by the Administration and resource partners to mitigate these effects; and (B) with respect to the grant program under subsection (c)— (i) the efforts of the Administrator and the association or associations to develop and evolve an online resource for small business concerns; and (ii) the efforts of the Administrator and the association or associations to develop a training program for resource partner counselors, including the number of counselors trained. 1104. Waiver of matching funds requirement under the women’s business center program During the 3-month period beginning on the date of enactment of this Act, the requirement relating to obtaining cash contributions from non-Federal sources under section 29(c)(1) of the Small Business Act ( 15 U.S.C. 656(c)(1) 1105. Loan forgiveness (a) Definitions In this section— (1) the term covered 7(a) loan 15 U.S.C. 636(a) (2) the term covered period (3) the term eligible recipient (4) the term payroll costs (A) the compensation of an individual employee in excess of $33,333 during the covered period; (B) qualified sick leave wages for which a credit is allowed under section 7001 of the Families First Coronavirus Response Act; or (C) qualified family leave wages for which a credit is allowed under section 7003 of the Families First Coronavirus Response Act. (b) Forgiveness An eligible recipient shall be eligible for forgiveness of indebtedness on a covered 7(a) loan in an amount equal to the cost of maintaining payroll continuity during the covered period. (c) Treatment of amounts forgiven (1) In general Amounts which have been forgiven under this section shall be considered canceled indebtedness by lenders authorized under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (2) For purposes of redemption of guarantees For purposes of the redemption of a guarantee by the lender for a covered 7(a) loan, amounts which are forgiven under this section shall be treated as a default, in accordance with the procedures that are otherwise applicable to a default on a loan guaranteed under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (d) Limits on amount of forgiveness (1) In general The amount of loan forgiveness under this section for an eligible recipient shall not exceed the sum of— (A) the total payroll costs incurred by the eligible recipient during the covered period; and (B) the amount of payments made during the covered period on debt obligations that were incurred before the covered period. (2) Reduction based on reduction in number of employees (A) In general The amount of loan forgiveness under this section shall be reduced by the percentage equal to the difference obtained by subtracting— (i) the quotient obtained by dividing— (I) the average number of full-time equivalent employees per month employed by the eligible recipient during the covered period; by (II) (aa) the average number of full time equivalent employees per month employed by the eligible recipient during the period beginning on March 1, 2019 and ending on June 30, 2019; or (bb) in the case of an eligible recipient that is seasonal employer, as determined by the Administrator, the average number of full-time equivalent employees per month employed by the eligible recipient during the period beginning on March 1, 2019 and ending on June 30, 2019; from (ii) 1. (B) Calculation of average number of employees The average number of full-time equivalent employees shall be determined by calculating the average number of employees for each pay period falling within a month. (3) Reduction relating to compensation The amount of loan forgiveness under this section shall also be reduced by the amount of any reduction in excess of 25 percent of compensation in the most recent full quarter in which the employee was paid in compensation during the covered period of any employee who was compensated— (A) in an amount less than $33,333 during the period beginning on March 1, 2019 and ending on June 30, 2019; or (B) not more than $100,000 on annualized basis during 2019. (4) Exception for tipped workers An eligible recipient with tipped employees described in section 3(m)(2)(A) of the Fair Labor Standards Act of 1938 ( 29 U.S.C. 203(m)(2)(A) (e) Application An eligible recipient seeking loan forgiveness under this section shall submit to the lender that originated the covered 7(a) loan an application, which shall include documentation verifying the number of full-time equivalent employees on payroll and pay rates for the periods described in subsection (d), including— (1) payroll tax filings reported to the Internal Revenue Service; (2) State income, payroll, and unemployment insurance filings; (3) financial statements verifying payment on debt obligations incurred before the covered period; and (4) any other documentation the Administrator determines necessary. (f) Certification An eligible recipient receiving loan forgiveness under this section shall make a good faith certification that the uncertainty of current economic conditions justifies the loan request to support the ongoing operations of the borrower, and acknowledges that funds will be used to retain workers and maintain payroll. (g) Prohibition on forgiveness without documentation No eligible recipient shall receive forgiveness under this section without submitting to the lender that originated the covered 7(a) loan the documentation required under subsection (e). (h) Decision Not later than 15 days after the date on which a lender receives an application for loan forgiveness under this section from an eligible recipient, the lender shall issue a decision on the an application. (i) Taxability Canceled indebtedness under this section shall be excluded from gross income for purposes of the Internal Revenue Code of 1986. (j) Rule of construction The cancellation of indebtedness on a covered 7(a) loan under this section shall not otherwise modify the terms and conditions of the covered 7(a) loan. (k) Regulations Not later than 30 days after the date of enactment of this Act, the Administrator shall issue guidance and regulations implementing this section. 1106. Direct appropriations (a) In general There is appropriated, out of amounts in the Treasury not otherwise appropriated, for the fiscal year ending September 30, 2020, to remain available until September 30, 2021, for additional amounts— (1) $299,400,000,000 under the heading Small Business Administration—Business Loans Program Account 15 U.S.C. 636(a) (2) $300,000,000 under the heading Small Business Administration—Salaries and Expenses (3) $25,000,000 under the heading Small Business Administration—Office of Inspector General (4) $265,000,000 under the heading Small Business Administration—Entrepreneurial Development Programs (A) $240,000,000 shall be for carrying section 1103(b) of this Act; and (B) $25,000,000 shall be for carrying out section 1103(c) of this Act; and (5) $10,000,000 under the heading Department of Commerce—Minority Business Development Agency (b) Reports Not later than 180 days after the date of enactment of this Act, the Administrator shall submit to the Committee on Appropriations of the Senate and the Committee on Appropriations of the House of Representatives a detailed expenditure plan for using the amounts appropriated under subsection (a). 1107. Minority business development agency (a) Definitions In this section— (1) the term Agency (2) the term covered small business concern 15 U.S.C. 632 (3) the term minority business center (4) the term substantially affected by COVID–19 (A) supply chain disruptions, including changes in— (i) quantity and lead time, including the number of shipments of components and delays in shipments; (ii) quality, including shortages in supply for quality control reasons; and (iii) technology, including a compromised payment network; (B) staffing challenges; (C) a decrease in sales or customers; or (D) shuttered businesses. (b) Education, training, and advising grants (1) In general The Agency may provide financial assistance in the form of grants to minority business centers to provide education, training, and advising to covered small business concerns. (2) Use of funds Grants under this section shall be used for the education, training, and advising of covered small business concerns and their employees on— (A) accessing and applying for resources provided by the Agency and other Federal resources relating to access to capital and business resiliency; (B) the hazards and prevention of the transmission and communication of COVID–19 and other communicable diseases; (C) the potential effects of COVID–19 on the supply chains, distribution, and sale of products of covered small business concerns and the mitigation of those effects; (D) the management and practice of telework to reduce possible transmission of COVID–19; (E) the management and practice of remote customer service by electronic or other means; (F) the risks of and mitigation of cyber threats in remote customer service or telework practices; (G) the mitigation of the effects of reduced travel or outside activities on covered small business concerns during COVID–19 or similar occurrences; and (H) any other relevant business practices necessary to mitigate the economic effects of COVID–19 or similar occurrences. (3) No matching funds required Matching funds shall not be required for any grant under this section. (4) Goals and metrics (A) In general Goals and metrics for the funds made available under this section shall be jointly developed, negotiated, and agreed upon, with full participation of both parties, between the minority business centers and the Agency, which shall— (i) take into consideration the extent of the circumstances relating to the spread of COVID–19, or similar occurrences, that affect covered small business concerns located in the areas covered by the minority business centers, particularly in rural areas or economically distressed areas; (ii) generally follow the use of funds outlined in paragraph (2), but shall not restrict the activities of minority business centers in responding to unique situations; and (iii) encourage minority business centers to develop and provide services to covered small business concerns. (B) Public availability The Agency shall make publicly available the methodology by which the Agency and minority business centers jointly develop the metrics and goals described in subparagraph (A). (5) Authorization of appropriations There is authorized to be appropriated $10,000,000 to carry out this section, to remain available until expended. 1108. Waiver of prepayment penalty Notwithstanding any other provision of law, for a loan made under the authority under this division or an amendment made by this division, there shall be no prepayment penalty for any payment on the loan made on or before December 31, 2020. 1109. United States Treasury Program Management Authority (a) Authority to include additional financial institutions The Department of the Treasury, in consultation with the Administration and the other Federal financial regulatory agencies (as defined in section 313(r) of title 31, United States Code), shall establish criteria for insured depository institutions (as defined in section 3 of the Federal Deposit Insurance Act ( 12 U.S.C. 1813 15 U.S.C. 636(a) 50 U.S.C. 1601 (b) Criteria Due to exigent circumstances, the eligibility criteria that would otherwise be applicable a loan made under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (c) Safety and soundness An insured depository institution (as defined in section 3 of the Federal Deposit Insurance Act ( 12 U.S.C. 1813 (d) Additional regulations The Secretary of the Treasury, in consultation with the Administrator, shall issue regulations and guidance in order to direct additional lenders under this section and establish additional terms that set out compensation, underwriting standards, interest rates, maturity, and other relevant terms and conditions. (e) Program administration Under the infrastructure of the Department of the Treasury and with guidance from the Secretary of the Treasury, the Administration shall administer the program established under this section until the date on which the national emergency declared by the President under the National Emergencies Act ( 50 U.S.C. 1601 B Relief for individuals, families, and businesses I Rebates and other individual provisions 2101. 2020 recovery rebates for individuals (a) In general Subchapter B of chapter 65 of subtitle F of the Internal Revenue Code of 1986 is amended by inserting after section 6427 the following new section: 6428. 2020 Recovery Rebates for individuals (a) In general In the case of an eligible individual, there shall be allowed as a credit against the tax imposed by subtitle A for the first taxable year beginning in 2020 an amount equal to the lesser of— (1) net income tax liability, or (2) $1,200 ($2,400 in the case of a joint return). (b) Special rules (1) In general In the case of a taxpayer described in paragraph (2)— (A) the amount determined under subsection (a) shall not be less than $600 ($1,200 in the case of a joint return), and (B) the amount determined under subsection (a) (after the application of subparagraph (A)) shall be increased by the product of $500 multiplied by the number of qualifying children (within the meaning of section 24(c)) of the taxpayer. (2) Taxpayer described A taxpayer is described in this paragraph if the taxpayer— (A) has qualifying income of at least $2,500, or (B) has— (i) net income tax liability which is greater than zero, and (ii) gross income which is greater than the basic standard deduction. (c) Treatment of credit The credit allowed by subsection (a) shall be treated as allowed by subpart C of part IV of subchapter A of chapter 1. (d) Limitation based on adjusted gross income The amount of the credit allowed by subsection (a) (determined without regard to this subsection and subsection (f)) shall be reduced (but not below zero) by 5 percent of so much of the taxpayer’s adjusted gross income as exceeds $75,000 ($150,000 in the case of a joint return). (e) Definitions For purposes of this section— (1) Qualifying income The term qualifying income (A) earned income, (B) social security benefits (within the meaning of section 86(d)), and (C) any compensation or pension received under chapter 11, chapter 13, or chapter 15 (2) Net income tax liability The term net income tax liability (A) the sum of the taxpayer’s regular tax liability (within the meaning of section 26(b)) and the tax imposed by section 55 for the taxable year, over (B) the credits allowed by part IV (other than section 24 and subpart C thereof) of subchapter A of chapter 1. (3) Eligible individual The term eligible individual (A) any nonresident alien individual, (B) any individual with respect to whom a deduction under section 151 is allowable to another taxpayer for a taxable year beginning in the calendar year in which the individual’s taxable year begins, and (C) an estate or trust. (4) Earned income The term earned income (5) Basic standard deduction The term basic standard deduction (f) Coordination with advance refunds of credit (1) In general The amount of credit which would (but for this paragraph) be allowable under this section shall be reduced (but not below zero) by the aggregate refunds and credits made or allowed to the taxpayer under subsection (g). Any failure to so reduce the credit shall be treated as arising out of a mathematical or clerical error and assessed according to section 6213(b)(1). (2) Joint returns In the case of a refund or credit made or allowed under subsection (g) with respect to a joint return, half of such refund or credit shall be treated as having been made or allowed to each individual filing such return. (g) Advance refunds and credits (1) In general Subject to paragraph (5), each individual who was an eligible individual for such individual’s first taxable year beginning in 2018 shall be treated as having made a payment against the tax imposed by chapter 1 for such first taxable year in an amount equal to the advance refund amount for such taxable year. (2) Advance refund amount For purposes of paragraph (1), the advance refund amount is the amount that would have been allowed as a credit under this section for such first taxable year if this section (other than subsection (f) and this subsection) had applied to such taxable year. (3) Timing of payments The Secretary shall, subject to the provisions of this title, refund or credit any overpayment attributable to this section as rapidly as possible. No refund or credit shall be made or allowed under this subsection after December 31, 2020. (4) No interest No interest shall be allowed on any overpayment attributable to this section. (5) Alternate taxable year In the case of an individual who, at the time of any determination made pursuant to paragraph (3), has not filed a tax return for the year described in paragraph (1), the Secretary may apply such paragraph by substituting 2019 2018 (h) Identification number requirement (1) In general No credit shall be allowed under subsection (a) to an eligible individual who does not include on the return of tax for the taxable year— (A) such individual’s valid identification number, (B) in the case of a joint return, the valid identification number of such individual’s spouse, and (C) in the case of any qualifying child taken into account under subsection (b)(1)(B), the valid identification number of such qualifying child. (2) Valid identification number (A) In general For purposes of paragraph (1), the term valid identification number (B) Adoption taxpayer identification number For purposes of paragraph (1)(C), in the case of a qualifying child who is adopted, the term valid identification number (i) Regulations The Secretary shall prescribe such regulations or other guidance as may be necessary to carry out the purposes of this section. . (b) Administrative amendments (1) Definition of deficiency Section 6211(b)(4)(A) and 36B, 168(k)(4) 36B, and 6428 (2) Mathematical or clerical error authority Section 6213(g)(2)(L) of such Code is amended by striking or 32 32, or 6428 (c) Treatment of possessions (1) Payments to possessions (A) Mirror code possession The Secretary of the Treasury shall pay to each possession of the United States which has a mirror code tax system amounts equal to the loss (if any) to that possession by reason of the amendments made by this section. Such amounts shall be determined by the Secretary of the Treasury based on information provided by the government of the respective possession. (B) Other possessions The Secretary of the Treasury shall pay to each possession of the United States which does not have a mirror code tax system amounts estimated by the Secretary of the Treasury as being equal to the aggregate benefits (if any) that would have been provided to residents of such possession by reason of the amendments made by this section if a mirror code tax system had been in effect in such possession. The preceding sentence shall not apply unless the respective possession has a plan, which has been approved by the Secretary of the Treasury, under which such possession will promptly distribute such payments to its residents. (2) Coordination with credit allowed against United States income taxes No credit shall be allowed against United States income taxes under section 6428 (A) to whom a credit is allowed against taxes imposed by the possession by reason of the amendments made by this section, or (B) who is eligible for a payment under a plan described in paragraph (1)(B). (3) Definitions and special rules (A) Possession of the United States For purposes of this subsection, the term possession of the United States (B) Mirror code tax system For purposes of this subsection, the term mirror code tax system (C) Treatment of payments For purposes of section 1324 of title 31, United States Code, the payments under this section shall be treated in the same manner as a refund due from a credit provision referred to in subsection (b)(2) of such section. (d) Exception from Treasury Offset Program Any credit or refund allowed or made to any individual by reason of section 6428 (1) section 3716 or 3720A of title 31, United States Code, or (2) subsection (d), (e), or (f) of section 6402 (e) Appropriations to carry out rebates (1) In general Immediately upon the enactment of this Act, the following sums are appropriated, out of any money in the Treasury not otherwise appropriated, for the fiscal year ending September 30, 2020: (A) Department of the Treasury (i) For an additional amount for Department of the Treasury—Bureau of the Fiscal Service—Salaries and Expenses (ii) For an additional amount for Department of the Treasury—Internal Revenue Service—Taxpayer Services (iii) For an additional amount for Department of the Treasury—Internal Revenue Service—Operations Support (B) Social security administration For an additional amount for Social Security Administration—Limitation on Administrative Expenses (2) Reports No later than 15 days after enactment of this Act, the Secretary of the Treasury shall submit a plan to the Committees on Appropriations of the House of Representatives and the Senate detailing the expected use of the funds provided by paragraph (1)(A). Beginning 90 days after enactment of this Act, the Secretary of the Treasury shall submit a quarterly report to the Committees on Appropriations of the House of Representatives and the Senate detailing the actual expenditure of funds provided by paragraph (1)(A) and the expected expenditure of such funds in the subsequent quarter. (f) Conforming amendments (1) Paragraph (2) of section 1324(b) of title 31, United States Code, is amended by inserting “6428,” after “54B(h),”. (2) The table of sections for subchapter B of chapter 65 of subtitle F of the Internal Revenue Code of 1986 is amended by inserting after the item relating to section 6427 the following: Sec. 6428. 2020 Recovery Rebates for individuals. . 2102. Delay of certain deadlines (a) Filing deadlines for 2019 (1) In general In the case of returns for taxable year 2019, including for purposes of section 6151(a) (A) by substituting July April (B) by substituting the seventh month the fourth month (2) Effective date Paragraph (1) shall apply to all returns required to be filed for taxable year 2019. (b) Estimated tax payments for individuals (1) In general In the case of an individual, the due date for any required installment under section 6654 (2) Applicable period For purposes of this subsection, the applicable period is the period beginning on the date of the enactment of this Act and ending before October 15, 2020. 2103. Special rules for use of retirement funds (a) Tax-favored withdrawals from retirement plans (1) In general Section 72(t) (2) Aggregate dollar limitation (A) In general For purposes of this subsection, the aggregate amount of distributions received by an individual which may be treated as coronavirus-related distributions for any taxable year shall not exceed $100,000. (B) Treatment of plan distributions If a distribution to an individual would (without regard to subparagraph (A)) be a coronavirus-related distribution, a plan shall not be treated as violating any requirement of the Internal Revenue Code of 1986 merely because the plan treats such distribution as a coronavirus-related distribution, unless the aggregate amount of such distributions from all plans maintained by the employer (and any member of any controlled group which includes the employer) to such individual exceeds $100,000. (C) Controlled group For purposes of subparagraph (B), the term controlled group section 414 (3) Amount distributed may be repaid (A) In general Any individual who receives a coronavirus-related distribution may, at any time during the 3-year period beginning on the day after the date on which such distribution was received, make 1 or more contributions in an aggregate amount not to exceed the amount of such distribution to an eligible retirement plan of which such individual is a beneficiary and to which a rollover contribution of such distribution could be made under section 402(c), 403(a)(4), 403(b)(8), 408(d)(3), or 457(e)(16), of the Internal Revenue Code of 1986, as the case may be. (B) Treatment of repayments of distributions from eligible retirement plans other than IRAs For purposes of the Internal Revenue Code of 1986, if a contribution is made pursuant to subparagraph (A) with respect to a coronavirus-related distribution from an eligible retirement plan other than an individual retirement plan, then the taxpayer shall, to the extent of the amount of the contribution, be treated as having received the coronavirus-related distribution in an eligible rollover distribution (as defined in section 402(c)(4) of such Code) and as having transferred the amount to the eligible retirement plan in a direct trustee to trustee transfer within 60 days of the distribution. (C) Treatment of repayments of distributions from IRAs For purposes of the Internal Revenue Code of 1986, if a contribution is made pursuant to subparagraph (A) with respect to a coronavirus-related distribution from an individual retirement plan (as defined by section 7701(a)(37) of such Code), then, to the extent of the amount of the contribution, the coronavirus-related distribution shall be treated as a distribution described in section 408(d)(3) of such Code and as having been transferred to the eligible retirement plan in a direct trustee to trustee transfer within 60 days of the distribution. (4) Definitions For purposes of this subsection— (A) Coronavirus-related distribution Except as provided in paragraph (2), the term coronavirus-related distribution (i) on or after the date of the enactment of this Act and before December 31, 2020, (ii) to an individual— (I) who is diagnosed with the virus SARS-CoV-2 or with coronavirus disease 2019 (COVID-19) by a test approved by the Centers for Disease Control and Prevention, (II) whose spouse or dependent (as defined in section 152 (III) who experiences adverse financial consequences as a result of being quarantined, being furloughed or laid off or having work hours reduced due to such virus or disease, being unable to work due to lack of child care due to such virus or disease, closing or reducing hours of a business owned or operated by the individual due to such virus or disease, or other factors as determined by the Secretary of the Treasury (or the Secretary's delegate). (B) Eligible retirement plan The term eligible retirement plan section 402(c)(8)(B) (5) Income inclusion spread over 3-year period (A) In general In the case of any coronavirus-related distribution, unless the taxpayer elects not to have this paragraph apply for any taxable year, any amount required to be included in gross income for such taxable year shall be so included ratably over the 3-taxable-year period beginning with such taxable year. (B) Special rule For purposes of subparagraph (A), rules similar to the rules of subparagraph (E) of section 408A(d)(3) (6) Special rules (A) Exemption of distributions from trustee to trustee transfer and withholding rules For purposes of sections 401(a)(31), 402(f), and 3405 of the Internal Revenue Code of 1986, coronavirus-related distributions shall not be treated as eligible rollover distributions. (B) Coronavirus-related distributions treated as meeting plan distribution requirements For purposes of the Internal Revenue Code of 1986, a coronavirus-related distribution shall be treated as meeting the requirements of sections 401(k)(2)(B)(i), 403(b)(7)(A)(i), 403(b)(11), and 457(d)(1)(A) of such Code. (b) Loans from qualified plans (1) Increase in limit on loans not treated as distributions In the case of any loan from a qualified employer plan (as defined under section 72(p)(4) (A) clause (i) of section 72(p)(2)(A) of such Code shall be applied by substituting $100,000 $50,000 (B) clause (ii) of such section shall be applied by substituting the present value of the nonforfeitable accrued benefit of the employee under the plan one-half of the present value of the nonforfeitable accrued benefit of the employee under the plan (2) Delay of repayment In the case of a qualified individual with an outstanding loan (on or after the date of the enactment of this Act) from a qualified employer plan (as defined in section 72(p)(4) (A) if the due date pursuant to subparagraph (B) or (C) of section 72(p)(2) of such Code for any repayment with respect to such loan occurs during the period beginning on the date of the enactment of this Act and ending on December 31, 2020, such due date shall be delayed for 1 year (or, if later, until the date which is 180 days after the date of the enactment of this Act), (B) any subsequent repayments with respect to any such loan shall be appropriately adjusted to reflect the delay in the due date under subparagraph (A) and any interest accruing during such delay, and (C) in determining the 5-year period and the term of a loan under subparagraph (B) or (C) of section 72(p)(2) of such Code, the period described in subparagraph (A) of this paragraph shall be disregarded. (3) Qualified individual For purposes of this subsection, the term qualified individual (c) Provisions relating to plan amendments (1) In general If this subsection applies to any amendment to any plan or annuity contract, such plan or contract shall be treated as being operated in accordance with the terms of the plan during the period described in paragraph (2)(B)(i). (2) Amendments to which subsection applies (A) In general This subsection shall apply to any amendment to any plan or annuity contract which is made— (i) pursuant to any provision of this section, or pursuant to any regulation issued by the Secretary of the Treasury or the Secretary of Labor (or the delegate of either such Secretary) under any provision of this section, and (ii) on or before the last day of the first plan year beginning on or after January 1, 2020, or such later date as the Secretary of the Treasury (or the Secretary's delegate) may prescribe. In the case of a governmental plan (as defined in section 414(d) (B) Conditions This subsection shall not apply to any amendment unless— (i) during the period— (I) beginning on the date that this section or the regulation described in subparagraph (A)(i) takes effect (or in the case of a plan or contract amendment not required by this section or such regulation, the effective date specified by the plan), and (II) ending on the date described in subparagraph (A)(ii) (or, if earlier, the date the plan or contract amendment is adopted), the plan or contract is operated as if such plan or contract amendment were in effect, and (ii) such plan or contract amendment applies retroactively for such period. 2104. Allowance of partial above the line deduction for charitable contributions (a) In general Section 62(a) (22) Charitable contributions In the case of taxable years beginning in 2020, the amount (not to exceed $300) of qualified charitable contributions made by an eligible taxpayer during the taxable year . . (b) Definitions Section 62 of such Code is amended by adding at the end the following new subsection: (f) Definitions relating to qualified charitable contributions For purposes of subsection (a)(22)— (1) Eligible taxpayer The term eligible taxpayer (2) Qualified charitable contributions The term qualified charitable contribution (A) which is made in cash, (B) for which a deduction is allowable under section 170 (determined without regard to subsection (b) thereof), and (C) which is— (i) made to an organization described in section 170(b)(1)(A), and (ii) not— (I) to an organization described in section 509(a)(3), or (II) for the establishment of a new, or maintenance of an existing, donor advised fund (as defined in section 4966(d)(2)). Such term shall not include any amount which is treated as a charitable contribution made in such taxable year under subsection (b)(1)(G) or (d)(1) of section 170. . (c) Effective date The amendments made by this section shall apply to taxable years beginning after December 31, 2019. 2105. Modification of limitations on charitable contributions during 2020 (a) Temporary suspension of limitations on certain cash contributions (1) In general Except as otherwise provided in paragraph (2), qualified contributions shall be disregarded in applying subsections (b) and (d) of section 170 (2) Treatment of excess contributions For purposes of section 170 (A) Individuals In the case of an individual— (i) Limitation Any qualified contribution shall be allowed as a deduction only to the extent that the aggregate of such contributions does not exceed the excess of the taxpayer’s contribution base (as defined in subparagraph (H) of section 170(b)(1) of such Code) over the amount of all other charitable contributions allowed under section 170(b)(1) of such Code. (ii) Carryover If the aggregate amount of qualified contributions made in the contribution year (within the meaning of section 170(d)(1) of such Code) exceeds the limitation of clause (i), such excess shall be added to the excess described in section 170(b)(1)(G)(ii). (B) Corporations In the case of a corporation— (i) Limitation Any qualified contribution shall be allowed as a deduction only to the extent that the aggregate of such contributions does not exceed the excess of 25 percent of the taxpayer’s taxable income (as determined under paragraph (2) of section 170(b) of such Code) over the amount of all other charitable contributions allowed under such paragraph. (ii) Carryover If the aggregate amount of qualified contributions made in the contribution year (within the meaning of section 170(d)(2) of such Code) exceeds the limitation of clause (i), such excess shall be appropriately taken into account under section 170(d)(2) subject to the limitations thereof. (3) Qualified contributions (A) In general For purposes of this subsection, the term qualified contribution section 170(c) (i) such contribution is paid in cash during calendar year 2020 to an organization described in section 170(b)(1)(A) of such Code, and (ii) the taxpayer has elected the application of this section with respect to such contribution. (B) Exception Such term shall not include a contribution by a donor if the contribution is— (i) to an organization described in section 509(a)(3) (ii) for the establishment of a new, or maintenance of an existing, donor advised fund (as defined in section 4966(d)(2) of such Code). (C) Application of election to partnerships and s corporations In the case of a partnership or S corporation, the election under subparagraph (A)(ii) shall be made separately by each partner or shareholder. (b) Increase in limits on contributions of food inventory In the case of any charitable contribution of food during 2020 to which section 170(e)(3)(C) 25 percent 15 percent. (c) Effective date This section shall apply to taxable years ending after December 31, 2019. II Business provisions 2201. Delay of estimated tax payments for corporations (a) In general In the case of a corporation, the due date for any required installment under section 6655 (b) Applicable period For purposes of this section, the applicable period is the period beginning on the date of the enactment of this Act and ending before October 15, 2020. 2202. Delay of payment of employer payroll taxes (a) In general (1) Taxes Notwithstanding any other provision of law, the payment for applicable employment taxes for the payroll tax deferral period shall not be due before the applicable date. (2) Deposits Notwithstanding section 6302 (3) Exception This subsection shall not apply to any taxpayer if such taxpayer has had indebtedness forgiven under section 1105 of this Act with respect to a loan under section 7(a) of the Small Business Act ( 15 U.S.C. 636(a) (b) SECA (1) In general Notwithstanding any other provision of law, the payment for 50 percent of the taxes imposed under section 1401(a) (2) Estimated taxes For purposes of applying section 6654 (c) Definitions For purposes of this section— (1) Applicable employment taxes The term applicable employment taxes (A) The taxes imposed under section 3111(a) (B) So much of the taxes imposed under section 3211(a) of such Code as are attributable to the rate in effect under section 3111(a) of such Code. (C) So much of the taxes imposed under section 3221(a) of such Code as are attributable to the rate in effect under section 3111(a) of such Code. (2) Payroll tax deferral period The term payroll tax deferral period (3) Applicable date The term applicable date (A) December 31, 2021, with respect to 50 percent of the amounts to which subsection (a) or (b), as the case may be, apply, and (B) December 31, 2022, with respect to the remaining such amounts. (d) Trust funds held harmless There are hereby appropriated (out of any money in the Treasury not otherwise appropriated) for each fiscal year to the Federal Old-Age and Survivors Insurance Trust Fund and the Federal Disability Insurance Trust Fund established under section 201 of the Social Security Act ( 42 U.S.C. 401 45 U.S.C. 231n–1(a) (e) Regulatory authority The Secretary of the Treasury (or the Secretary's delegate) shall issue such regulations or other guidance as necessary to carry out the purposes of this section. 2203. Modifications for net operating losses (a) Temporary repeal of taxable income limitation (1) In general The first sentence of section 172(a) an amount equal to an amount equal to— (1) in the case of a taxable year beginning before January 1, 2021, the aggregate of the net operating loss carryovers to such year, plus the net operating loss carrybacks to such year, and (2) in the case of a taxable year beginning after December 31, 2020, the sum of— (A) the aggregate amount of net operating losses arising in taxable years beginning before January 1, 2018, carried to such taxable year, plus (B) the lesser of— (i) the aggregate amount of net operating losses arising in taxable years beginning after December 31, 2017, carried to such taxable year, or (ii) 80 percent of the excess (if any) of— (I) taxable income computed without regard to the deductions under this section and sections 199A and 250, over (II) the amount determined under subparagraph (A). . (2) Conforming amendments (A) Section 172(b)(2)(C) of such Code is amended to read as follows: (C) for taxable years beginning after December 31, 2020, be reduced by 20 percent of the excess (if any) described in subsection (a)(2)(B)(ii) for such taxable year. . (B) Section 172(d)(6)(C) of such Code is amended by striking subsection (a)(2) subsection (a)(2)(B)(ii)(I) (C) Section 860E(a)(3)(B) of such Code is amended by striking all that follows for purposes of subsection (a)(2)(B)(ii)(I) and the second sentence of subsection (b)(2) of section 172. (b) Modification of rules relating to carrybacks (1) In general Section 172(b)(1) (D) Special rule for losses arising in 2018, 2019, and 2020 (i) In general In the case of any net operating loss arising in a taxable year beginning after December 31, 2017, and before January 1, 2020— (I) such loss shall be a net operating loss carryback to each of the 5 taxable years preceding the taxable year of such loss, and (II) subparagraphs (B) and (C)(i) shall not apply. (ii) Special rules for REIT's For purposes of this subparagraph— (I) In general A net operating loss for a REIT year shall not be a net operating loss carryback to any taxable year preceding the taxable year of such loss. (II) Special rule In the case of any net operating loss for a taxable year which is not a REIT year, such loss shall not be carried back to any taxable year which is a REIT year. (III) REIT year For purposes of this subparagraph, the term REIT year (iii) Election A taxpayer may elect not to have clause (i) apply for any taxable year. Such election shall be made in such manner as prescribed by the Secretary and shall be made— (I) in the case of any election relating to a net operating loss arising in a taxable year beginning in 2018 or 2019, by the due date (including extensions of time) for filing the taxpayer's return for the first taxable year ending after the date of the enactment of this subparagraph, and (II) in the case of any election relating to a net operating loss arising in a taxable year beginning in 2020, by the due date (including extensions of time) for such taxable year. Such election, once made for any taxable year, shall be irrevocable for such taxable year. . (2) Conforming amendment Section 170(b)(1)(A) of such Code, as amended by subsection (c)(2), is amended by striking and (C)(i) , (C)(i), and (D) (c) Technical amendment relating to section 13302 Public Law 115–97 (1) Section 13302(e) of Public Law 115–97 (e) Effective dates (1) Net operating loss limitation The amendments made by subsections (a) and (d)(2) shall apply to— (A) taxable years beginning after December 31, 2017, and (B) taxable years beginning on or before December 31, 2017, to which net operating losses arising in taxable years beginning after December 31, 2017, are carried. (2) Carryforwards and carrybacks The amendments made by subsections (b), (c), and (d)(1) shall apply to net operating losses arising in taxable years beginning after December 31, 2017. . (2) Section 172(b)(1)(A) (A) General rule A net operating loss for any taxable year— (i) shall be a net operating loss carryback to the extent provided in subparagraphs (B) and (C)(i), and (ii) except as provided in subparagraph (C)(ii), shall be a net operating loss carryover— (I) in the case of a net operating loss arising in a taxable year beginning before January 1, 2018, to each of the 20 taxable years following the taxable year of the loss, and (II) in the case of a net operating loss arising in a taxable year beginning after December 31, 2017, to each taxable year following the taxable year of the loss. . (d) Effective dates (1) Net operating loss limitation The amendments made by subsection (a) shall apply— (A) to taxable years beginning after December 31, 2017, and (B) taxable years beginning on or before December 31, 2017, to which net operating losses arising in taxable years beginning after December 31, 2017, are carried. (2) Carryforwards and carrybacks The amendment made by subsection (b) shall apply to net operating losses arising in taxable years beginning after December 31, 2017. (3) Technical amendments The amendments made by subsection (c) shall take effect as if included in the provisions of Public Law 115–97 (4) Special rule In the case of a net operating loss arising in a taxable year beginning before January 1, 2018, and ending after December 31, 2017— (A) an application under section 6411(a) (B) an election to— (i) forgo any carryback of such net operating loss, (ii) reduce any period to which such net operating loss may be carried back, or (iii) revoke any election made under section 172(b) to forgo any carryback of such net operating loss, shall not fail to be treated as timely made if made not later than the date which is 120 days after the date of the enactment of this Act. 2204. Modification of limitation on losses for taxpayers other than corporations (a) In general Section 461(l)(1) December 31, 2017 December 31, 2020 (b) Technical amendments relating to section 11012 Public Law 115–97 (1) Section 461(l)(2) a net operating loss carryover to the following taxable year under section 172 a net operating loss for the taxable year for purposes of determining any net operating loss carryover under section 172(b) for subsequent taxable years (2) Section 461(l)(3)(A) of such Code is amended— (A) in clause (i), by inserting and without regard to any deduction allowable under section 172 or 199A under paragraph (1) (B) by adding at the end the following flush sentence: Such excess shall be determined without regard to any deductions, gross income, or gains attributable to any trade or business of performing services as an employee. . (3) Section 461(l)(3) of such Code is amended by redesignating subparagraph (B) as subparagraph (C) and by inserting after subparagraph (A) the following new subparagraph: (B) Treatment of capital gains and losses (i) Losses Deductions for losses from sales or exchanges of capital assets shall not be taken into account under subparagraph (A)(i). (ii) Gains The amount of gains from sales or exchanges of capital assets taken into account under subparagraph (A)(ii) shall not exceed the lesser of— (I) the capital gain net income determined by taking into account only gains and losses attributable to a trade or business, or (II) the capital gain net income. . (c) Effective dates (1) In general The amendments made by subsection (a) shall apply to taxable years beginning after December 31, 2017. (2) Technical amendments The amendments made by subsection (b) shall take effect as if included in the provisions of Public Law 115–97 2205. Modification of credit for prior year minimum tax liability of corporations (a) In general Section 53(e) (e) Credit treated as refundable for certain taxpayers In the case of the first taxable year of a corporation beginning in 2018— (1) subsection (c) shall not apply, and (2) for purposes of this title (other than this section), the credit allowed by reason of this subsection shall be treated as allowed under subpart C (and not this subpart). . (b) Effective date The amendment made by this section shall apply to taxable years beginning after December 31, 2017. 2206. Modification of limitation on business interest (a) In general Section 163(j) (10) Special rule for taxable years beginning in 2019 and 2020 (A) In general In the case of any taxable year beginning in 2019 or 2020, paragraph (1)(B) shall be applied by substituting 50 percent 30 percent (B) Election to use 2019 income for taxable years beginning in 2020 (i) In general Subject to clause (ii), in the case of any taxable year beginning in 2020, the taxpayer may elect to apply this subsection by substituting the adjusted taxable income of the taxpayer for the last taxable year beginning in 2019 for the adjusted taxable income for such taxable year. (ii) Special rule for short taxable years No election may be made under clause (i) with respect to any taxable year beginning in 2020 if such taxable year is a short taxable year. . (b) Effective date The amendments made by this section shall apply to taxable years beginning after December 31, 2018. 2207. Technical amendments regarding qualified improvement property (a) In general Section 168 (1) in subsection (e)— (A) in paragraph (3)(E), by striking and , and (vii) any qualified improvement property. , and (B) in paragraph (6)(A), by inserting made by the taxpayer any improvement (2) in the table contained in subsection (g)(3)(B)— (A) by striking the item relating to subparagraph (D)(v), and (B) by inserting after the item relating to subparagraph (E)(vi) the following new item: (E)(vii) 20 . (b) Effective date The amendments made by this section shall take effect as if included in section 13204 of Public Law 115–97 2208. Installments not to prevent credit or refund of overpayments or increase estimated taxes (a) In general Section 965(h) (7) Installments not to prevent credit or refund of overpayments or increase estimated taxes If an election is made under paragraph (1) to pay the net tax liability under this section in installments— (A) no installment of such net tax liability shall— (i) in the case of a request for credit or refund, be taken into account as a liability for purposes of determining whether an overpayment exists for purposes of section 6402 before the date on which such installment is due, or (ii) for purposes of sections 6425, 6654, and 6655, be treated as a tax imposed by section 1, section 11, or subchapter L of chapter 1, and (B) the first sentence of section 6403 shall not apply with respect to any such installment. . (b) Limitation on payment of interest In the case of the portion of any overpayment which exists by reason of the application of section 965(h)(7) (1) if credit or refund of such portion is made on or before the date which is 45 days after the date of the enactment of this Act, no interest shall be allowed or paid under section 6611 of such Code with respect to such portion; and (2) if credit or refund of such portion is made after the date which is 45 days after the date of the enactment of this Act, no interest shall be allowed or paid under section 6611 of such Code with respect to such portion for any period before the date of the enactment of this Act. (c) Effective date The amendment made by subsection (a) shall take effect as if included in section 14103 of Public Law 115–97 2209. Restoration of limitation on downward attribution of stock ownership in applying constructive ownership rules (a) In general Section 958(b) (1) by inserting after paragraph (3) the following: (4) Subparagraphs (A), (B), and (C) of section 318(a)(3) shall not be applied so as to consider a United States person as owning stock which is owned by a person who is not a United States person. , and (2) by striking Paragraph (1) Paragraphs (1) and (4) (b) Foreign controlled United States shareholders Subpart F of part III of subchapter N of chapter 1 of such Code is amended by inserting after section 951A the following new section: 951B. Amounts included in gross income of foreign controlled United States shareholders (a) In general In the case of any foreign controlled United States shareholder of a foreign controlled foreign corporation— (1) this subpart (other than sections 951A, 951(b), 957, and 965) shall be applied with respect to such shareholder (separately from, and in addition to, the application of this subpart without regard to this section)— (A) by substituting foreign controlled United States shareholder United States shareholder (B) by substituting foreign controlled foreign corporation controlled foreign corporation (2) sections 951A and 965 shall be applied with respect to such shareholder — (A) by treating each reference to United States shareholder (B) by treating each reference to controlled foreign corporation (b) Foreign controlled United States shareholder For purposes of this section, the term foreign controlled United States shareholder (1) section 951(b) were applied by substituting more than 50 percent 10 percent or more (2) section 958(b) were applied without regard to paragraph (4) thereof. (c) Foreign controlled foreign corporation For purposes of this section, the term foreign controlled foreign corporation (1) by substituting foreign controlled United States shareholders United States shareholders (2) by substituting section 958(b) (other than paragraph (4) thereof) section 958(b) (d) Regulations The Secretary shall prescribe such regulations or other guidance as may be necessary or appropriate to carry out the purposes of this section, including regulations or other guidance— (1) to treat a foreign controlled United States shareholder or a foreign controlled foreign corporation as a United States shareholder or as a controlled foreign corporation, respectively, for purposes of provisions of this title other than this subpart, and (2) to prevent the avoidance of the purposes of this section. . (c) Clerical amendment The table of sections for subpart F of part III of subchapter N of chapter 1 of such Code is amended by inserting after the item relating to section 951A the following new item: Sec. 951B. Amounts included in gross income of foreign controlled United States shareholders. . (d) Effective date The amendments made by this section shall apply to— (1) the last taxable year of foreign corporations beginning before January 1, 2018, and each subsequent taxable year of such foreign corporations, and (2) taxable years of United States persons in which or with which such taxable years of foreign corporations end. C Assistance to severely distressed sectors of the United States economy I Economic Stabilization 3101. Short title This title may be cited as the Coronavirus Economic Stabilization Act of 2020 3102. Emergency relief through loans and loan guarantees (a) In general Notwithstanding any other provision of law, to provide liquidity to eligible businesses related to losses incurred as a direct result of coronavirus, the Secretary is authorized to make or guarantee loans to eligible businesses that do not, in the aggregate, exceed $208,000,000,000 and provide the subsidy amounts necessary for such loans and loan guarantees in accordance with the provisions of the Federal Credit Reform Act of 1990 ( 2 U.S.C. 661 (b) Distribution of loans and loan guarantees Loans and loan guarantees made pursuant to subsection (a) shall be made available to eligible business as follows: (1) Not more than $50,000,000,000 shall be available for passenger air carriers. (2) Not more than $8,000,000,000 shall be available for cargo air carriers. (3) Not more than $150,000,000,000 shall be available for other eligible businesses. (c) Loans and loan guarantees (1) In general The Secretary shall review and decide on applications for loans and loan guarantees under this section and may enter into agreements to make or guarantee loans to one or more obligors if the Secretary determines, in the Secretary's discretion, that— (A) the obligor is a eligible business for which credit is not reasonably available at the time of the transaction; (B) the intended obligation by the obligor is prudently incurred; and (C) the loan is sufficiently secured. (2) Terms and limitations (A) Forms; terms and conditions A loan or loan guarantee shall be issued under this section in such form and on such terms and conditions and contain such covenants, representatives, warranties, and requirements (including requirements for audits) as the Secretary determines appropriate. Any loans made by the Secretary under this section shall be at a rate not less than a rate determined by the Secretary taking into consideration the current average yield on outstanding marketable obligations of the United States of comparable maturity. (B) Procedures As soon as practicable, but in no case later than 10 days after the date of enactment of this Act, the Secretary shall publish procedures for application and minimum requirements, which may be supplemented by the Secretary in the Secretary's discretion, for the making of loans and loan guarantees under this section. (d) Financial protection of government (1) In general To the extent feasible and practicable, the Secretary shall ensure that the Federal Government is compensated for the risk assumed in making loans and loan guarantees under this section. (2) Government participation in gains If an eligible business receives a loan or loan guarantee from the Federal Government under this section, the Secretary is authorized to enter into contracts under which the Federal Government, contingent on the financial success of the eligible business, would participate in the gains of the eligible business or its security holders through the use of such instruments as warrants, stock options, common or preferred stock, or other appropriate equity instruments. (e) Deposit of proceeds Amounts collected by the Secretary under this section, including the proceeds of investments, earnings, and interest collected, shall be deposited as follows: (1) Amounts collected from eligible businesses that received loans or loan guarantees under paragraph (1) or (2) of subsection (b) shall be deposited in the Airport and Airway Trust Fund under section 9502 (2) Amounts collected from eligible businesses that received loans or loan guarantees under paragraph (3) of subsection (b) shall be deposited in the Treasury as miscellaneous receipts. (f) Administrative expenses Notwithstanding any other provision of law, the Secretary may use $100,000,000 of the funds made available under this section to pay costs and administrative expenses associated with the provision of direct loans or guarantees authorized under this section. (g) Conforming amendment Section 10(a) of the Gold Reserve Act of 1934 ( 31 U.S.C. 5302(a) (1) by striking and section 3 (2) by inserting and the Coronavirus Economic Stabilization Act of 2020, and for investing 3103. Limitation on certain employee compensation (a) In general The Secretary may only enter into a loan or loan agreement under section 3102(a) with an eligible business after the eligible business enters into a legally binding agreement with the Secretary that, during the 2-year period beginning March 1, 2020, and ending March 1, 2022, no officer or employee of the eligible business whose total compensation exceeded $425,000 in calendar year 2019 (other than an employee whose compensation is determined through an existing collective bargaining agreement entered into prior to March 1, 2020)— (1) will receive from the eligible business total compensation which exceeds, during any 12 consecutive months of such 2-year period, the total compensation received by the officer or employee from the eligible business in calendar year 2019; and (2) will receive from the eligible business severance pay or other benefits upon termination of employment with the eligible business which exceeds twice the maximum total compensation received by the officer or employee from the eligible business in calendar year 2019. (b) Total compensation defined In this section, the term total compensation 3104. Continuation of certain air service The Secretary of Transportation is authorized to require, to the extent reasonable and practicable, an air carrier receiving loans and loan guarantees under section 3102 to maintain scheduled air transportation service as the Secretary of Transportation deems necessary to ensure services to any point served by that carrier before March 1, 2020. When considering whether to exercise the authority granted by this section, the Secretary of Transportation shall take into consideration the air transportation needs of small and remote communities. 3105. Reports (a) Secretary The Secretary shall, with respect to the loans and loan guarantees provided under section 3102, make such reports as are required under section 5302 or title 31, United States Code. (b) Government accountability office (1) Study The Comptroller General of the United States shall conduct a study on the loans and loan guarantees provided under section 3102. (2) Report Not later than 9 months after the date of enactment of this Act, and annually thereafter through the year succeeding the last year for which loans or loan guarantees provided under section 3102 are in effect, the Comptroller General shall submit to the Committee on Transportation and Infrastructure, the Committee on Appropriations, and the Committee on the Budget of the House of Representatives and the Committee on Commerce, Science, and Transportation, the Committee on Appropriations, and the Committee on the Budget of the Senate a report on the loans and loan guarantees provided under section 3102. 3106. Coordination with Secretary of Transportation In implementing this title with respect to air carriers, the Secretary shall coordinate with the Secretary of Transportation. 3107. Definitions In this title: (1) Air carrier The term air carrier (2) Coronavirus The term coronavirus (3) Covered loss The term covered loss (4) Eligible business The term eligible business (A) an air carrier; or (B) a United States business that has incurred covered losses such that the continued operations of the business are jeopardized, as determined by the Secretary, and that has not otherwise applied for or received economic relief in the form of loans or loan guarantees provided under any other provision of this Act. (5) Secretary The term Secretary 3108. Rule of construction Nothing in this title shall be construed to allow the Secretary to provide relief to eligible businesses except in the form of secured loans and loan guarantees as provided in this title and under terms and conditions that are in the interest of the Federal Government. II Aviation excise taxes 3201. Suspension of certain aviation excise taxes (a) Transportation by air In the case of any payment for transportation by air (including any amount treated as paid for transportation by air by reason of section 4261(e)(3) (b) Use of kerosene in commercial aviation In the case of kerosene used in commercial aviation (as defined in section 4083 (1) no tax shall be imposed on such kerosene under— (A) section 4041(c) (B) section 4081 of such Code (other than at the rate provided in subsection (a)(2)(B) thereof), and (2) section 6427(l) of such Code shall be applied— (A) by treating such use as a nontaxable use, and (B) without regard to paragraph (4)(A)(ii) thereof. (c) Excise tax holiday period For purposes of section, the term excise tax holiday period D Health care response I Health provisions A Addressing supply shortages I Moving the strategic national stockpile to ASPR 4101. Moving the strategic national stockpile to ASPR Section 319F–2(a)(1) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(1)) is amended by striking The Secretary, in collaboration with the Assistant Secretary for Preparedness and Response and the Director of the Centers for Disease Control and Prevention, and in coordination with the Secretary of Homeland Security (referred to in this section as the Homeland Security Secretary The Secretary, in collaboration with the Assistant Secretary for Preparedness and Response, and in coordination with the Secretary of Homeland Security (referred to in this section as the Homeland Security Secretary II Medical product supplies 4111. National Academies report on America’s medical product supply chain security (a) In general Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the National Academies (b) Purposes The report developed under this section shall— (1) assess and evaluate the dependence of the United States, including the private commercial sector, States, and the Federal Government, on critical drugs and devices that are sourced or manufactured outside of the United States, which may include an analysis of— (A) the supply chain of critical drugs and devices of greatest priority to providing health care; (B) any potential public health security or national security risks associated with reliance on critical drugs and devices sourced or manufactured outside of the United States, which may include responses to previous or existing shortages or public health emergencies, such as infectious disease outbreaks, bioterror attacks, and other public health threats; (C) any existing supply chain information gaps, as applicable; and (D) potential economic impact of increased domestic manufacturing; and (2) provide recommendations, which may include a plan to improve the resiliency of the supply chain for critical drugs and devices as described in paragraph (1), and to address any supply vulnerabilities or potential disruptions of such products that would significantly affect or pose a threat to public health security or national security, as appropriate, which may include strategies to— (A) promote supply chain redundancy and contingency planning; (B) encourage domestic manufacturing, including consideration of economic impacts, if any; (C) improve supply chain information gaps; (D) improve planning considerations for medical product supply chain capacity during public health emergencies; and (E) promote the accessibility of such drugs and devices. (c) Input In conducting the study and developing the report under subsection (b), the National Academies shall— (1) consider input from the Department of Health and Human Services, the Department of Homeland Security, the Department of Defense, the Department of Commerce, the Department of State, the Department of Veterans Affairs, the Department of Justice, and any other Federal agencies as appropriate; and (2) consult with relevant stakeholders, which may include conducting public meetings and other forms of engagement, as appropriate, with health care providers, medical professional societies, State-based societies, public health experts, State and local public health departments, State medical boards, patient groups, medical product manufacturers, health care distributors, wholesalers and group purchasing organizations, pharmacists, and other entities with experience in health care and public health, as appropriate. (d) Definitions In this section, the terms device drug 21 U.S.C. 321 4112. Requiring the strategic national stockpile to include certain types of medical supplies Section 319F–2(a)(1) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(1)) is amended by inserting (including personal protective equipment, ancillary medical supplies, and other applicable supplies required for the administration of drugs, vaccines and other biological products, medical devices, and diagnostic tests in the stockpile) other supplies 4113. Treatment of respiratory protective devices as covered countermeasures Section 319F–3(i)(1) of the Public Health Service Act (42 U.S.C. 247d–6d(i)(1)) is amended— (1) in subparagraph (B), by striking or (2) in subparagraph (C), by striking the period at the end and inserting ; or (3) by adding at the end the following: (D) a respiratory protective device that is approved by the National Institute for Occupational Safety and Health under part 84 of title 42, Code of Federal Regulations (or any successor regulations), and that the Secretary determines to be a priority for use during a public health emergency declared pursuant to section 319. . III Mitigating emergency drug shortages 4121. Prioritize reviews of drug applications; incentives Section 506C(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c(g) (1) in paragraph (1), by striking the Secretary may the Secretary shall, as appropriate (2) in paragraph (1), by inserting prioritize and expedite the review (3) in paragraph (2), by inserting prioritize and expedite an inspection 4122. Additional manufacturer reporting requirements in response to drug shortages (a) Expansion To include active pharmaceutical ingredients Subsection (a) of section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c (1) in paragraph (1)(C), by inserting or any such drug that is critical to the public health during a public health emergency determined under section 319 of the Public Health Service Act during surgery (2) in the flush text at the end— (A) by inserting , or a discontinuance or an interruption in the manufacture of the active pharmaceutical ingredients of such drug, that is likely (B) by adding at the end the following: Notification under this subsection shall include disclosure of reasons for the discontinuation or interruption, as applicable; if an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation or interruption, the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known by the manufacturer; whether any associated medical devices used for preparation or administration included in the finished dosage form is a reason for, or a risk factor in, such discontinuation or interruption; the expected duration of the interruption; and such other information as the Secretary may require. (b) FOIA exemption Section 506C(d) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c(d) Information provided by a manufacturer to the Secretary under this section shall not be subject to disclosure under section 552 of title 5, United States Code. (c) Manufacturing contingency plans Section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c (j) Manufacturer contingency plans Each manufacturer of a drug described in subsection (a) or of any active pharmaceutical ingredient or any associated medical devices used for preparation or administration included in the finished dosage form of such a drug, shall maintain contingency and redundancy plans, as applicable, for each establishment in which such drugs or active pharmaceutical ingredients of such drugs are manufactured to help prevent or mitigate interruptions in the supply of the drug or ingredient. . (d) Annual notification Section 506E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356e (d) Interagency notification Not later than 180 days after the date of enactment of this subsection, and every 90 days thereafter, the Secretary shall transmit a report regarding the drugs of the current drug shortage list under this section to the Administrator of the Centers for Medicare & Medicaid Services. . (e) Reporting after inspections Section 704(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 374(b) (1) by redesignating paragraphs (1) and (2) and subparagraphs (A) and (B); (2) by striking (b) Upon completion (b)(1) Upon completion (3) by adding at the end the following: (2) In carrying out this subsection with respect to any establishment manufacturing a drug approved under subsection (c) or (j) of section 505 for which a notification has been submitted in accordance with section 506C is, or has been in the last 5 years, listed on the drug shortage list under section 506E, or that is described in section 505(j)(11)(A), a copy of the report shall be sent promptly to the appropriate offices of the Food and Drug Administration with expertise regarding drug shortages. Such offices shall ensure timely and effective coordination regarding the reviews of such report and overseeing the alignment of any feedback regarding such report, or corrective or preventative actions, after consideration of the systematic benefits and risks to public health, patient safety, the drug supply and drug supply chain, and timely patient access to such drugs. . (f) Effective date The amendments made by this section and section 4121 shall take effect on the date that is 180 days after the date of enactment of this Act. 4123. GAO report on intra-agency coordination (a) In general Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report examining the Food and Drug Administration's intra-agency coordination, communication, and decision making in assessing drug shortage risks, and taking corrective action. (b) Content The report shall include— (1) consideration of— (A) risks associated with violations of current good manufacturing practices; (B) corrective and preventative actions with respect to such violations requested by the Food and Drug Administration; (C) the effects of potential manufacturing slow-downs or shut-downs on potential drug shortages, including the discontinuance of drug manufacturing and marketing; (D) efforts to prioritize review of applications for drugs that the Secretary has determined under section 506E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356e (E) efforts to prioritize inspections of facilities necessary for approval of applications for drugs described in subparagraph (D); (2) a description of how the Food and Drug Administration proactively coordinates strategies to mitigate the consequences of the violations, slow-downs, and shut-downs described in paragraph (1) across agencies; and (3) an evaluation of changes in relevant Food and Drug Administration practices that such agency has proposed but not yet implemented. 4124. Report Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services, in coordination with the Commissioner of Food and Drugs and the Administrator of the Centers for Medicare & Medicaid Services, shall develop and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing recommendations— (1) for market-based incentives or other appropriate mechanisms, sufficient to encourage the manufacture of drugs in shortage or at risk of shortage; and (2) on how the Emerging Technology Program of the Food and Drug Administration can help facilitate creating or upgrading existing technologies to address drug shortage challenges and promote modern, reliable manufacturing strategies. 4125. Safe harbor provision (a) In general The Federal Food, Drug, and Cosmetic Act is amended by inserting after section 502 ( 21 U.S.C. 352 502A. Safe harbor provision (a) In general The communication of information, consistent with subsection (b), with respect to the use of a drug or device authorized under section 564 provided or distributed to a health care provider, shall not— (1) be a basis for treating such drug or device as misbranded under subsection (a) or (f) of section 502, or in violation of section 505, 515, or 564 of this Act or subsection (a) or (k) of section 351(a)(1) of the Public Health Service Act, as applicable; or (2) be treated as evidence that such drug or device is misbranded under subsection (a) or (f) of section 502, or in violation of section 505, 513, 515, or 564 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act, as applicable. (b) Provision of information (1) In general Any information relating to a use of a drug or device authorized under section 564, or for which a submission under section 564 has been submitted, that— (A) is neither false nor misleading, when measured objectively against the information available at the time the statement is made; (B) is accompanied, as required, by an appropriate disclaimer, as described in paragraph (2); and (C) is based on competent and reliable scientific evidence, as described in subsection (c). (2) Disclaimers For purposes of paragraph (1), such information shall be accompanied, as necessary, by an appropriate disclaimer, including— (A) a statement identifying any differences between the information and any labeling of the drug or device; (B) a statement identifying contradictory evidence; and (C) such other information as may be required by regulation. (c) Competent and reliable scientific evidence In this section, the term competent and reliable scientific evidence (1) regardless of whether it is supported by 2 adequate and well-controlled clinical studies; and (2) may include— (A) information derived from clinical trials, observational studies, clinical studies or bench tests that describe performance, database reviews, registries, patient utilization projections, and modeling techniques, and the data, inputs, and components of such information; (B) information about the effects of a drug or device in subgroups defined by demographic or other variables, including groups defined by race, sex, risk factors, or other variables, such as genomic features or disease severity; (C) information related to the emergency use authorization, as applicable; and (D) information relating to the safety, effectiveness, or benefit of a use or treatment that is authorized under section 564 for a drug or device, including information regarding— (i) health outcomes, patient or caregiver experience, or other quality metrics; and (ii) the comparative effectiveness of a drug or device relative to others products, other health care interventions, program and quality improvement interventions, or no intervention. (d) Distribution Information pursuant to subsection (b) may be distributed proactively through written or oral means, or other information platforms, to a health care provider, payor, formulary committee, or other similar entity carrying out responsibilities for making drug coverage, reimbursement, or usage decisions on a population basis. (e) Coverage not excluded The distribution of information that otherwise meets the requirements of this section shall not fail to meet the requirements of subsection (a) because the manufacturer or distributor of the drug or device about which information is being distributed has— (1) knowledge that such drug or device is being used by patients or health care practitioners in a manner not described in any labeling of the drug or device, as applicable; or (2) objective or subjective intent that such drug or device be used in a manner inconsistent with any labeling, as applicable, of such drug or device. (f) Rule of construction Nothing in this section shall be construed— (1) to limit communication not specifically permitted by this section; or (2) to alter or expand the authority of the Secretary to enforce the provisions of this Act, except to the extent that the communication of information in accordance with this section is permitted. . IV Preventing essential medical device shortages 4131. Discontinuance or interruption in the production of medical devices Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 506J. Discontinuance or interruption in the production of medical devices (a) In general A manufacturer of a device that— (1) is critical to public health during a public health emergency, including devices that are life-supporting, life-sustaining, or intended for use in emergency medical care or during surgery; or (2) for which the Secretary determines that information on potential meaningful supply disruptions of such device is needed during, or in advance of, a public health emergency; shall, during, or in advance of, a public health emergency determined by the Secretary pursuant to section 319, notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the device (except for discontinuances as a result of an approved modification of the device) or an interruption of the manufacture of the device that is likely to lead to a meaningful disruption in the supply of that device in the United States, and the reasons for such discontinuance or interruption. (b) Timing A notice required under subsection (a) shall be submitted to the Secretary— (1) at least 6 months prior to the date of the discontinuance or interruption; or (2) if compliance with paragraph (1) is not possible, as soon as practicable. (c) Distribution (1) Public availability To the maximum extent practicable, subject to paragraph (2), the Secretary shall distribute, through such means as the Secretary determines appropriate, information on the discontinuance or interruption of the manufacture of devices reported under subsection (a) to appropriate organizations, including physician, health provider, patient organizations, and supply chain partners, as appropriate and applicable. (2) Public health exception The Secretary may choose not to make information collected under this section publicly available pursuant to this section if the Secretary determines that disclosure of such information would adversely affect the public health, such as by increasing the possibility of unnecessary over purchase of product or other disruption of the availability of medical products to patients. (d) Confidentiality Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code. (e) Failure To meet requirements If a person fails to submit information required under subsection (a) in accordance with subsection (b)— (1) the Secretary shall issue a letter to such person informing such person of such failure; (2) not later than 30 calendar days after the issuance of a letter under paragraph (1), the person who receives such letter shall submit to the Secretary a written response to such letter setting forth the basis for noncompliance and providing information required under subsection (a); and (3) not later than 45 calendar days after the issuance of a letter under paragraph (1), the Secretary shall make such letter and any response to such letter under paragraph (2) available to the public on the internet website of the Food and Drug Administration, with appropriate redactions made to protect information described in subsection (d), except that, if the Secretary determines that the letter under paragraph (1) was issued in error or, after review of such response, the person had a reasonable basis for not notifying as required under subsection (a), the requirements of this paragraph shall not apply. (f) Expedited Inspections and Reviews If, based on notifications described in subsection (a) or any other relevant information, the Secretary concludes that there is, or is likely to be, a shortage of an device, the Secretary shall, as appropriate— (1) prioritize and expedite the review of a submission under section 513(f)(2), 515, review of a notification under section 510(k), or 520(m) for a device that could help mitigate or prevent such shortage; or (2) prioritize and expedite an inspection or reinspection of an establishment that could help mitigate or prevent such shortage. (g) Device shortage list (1) Establishment The Secretary shall establish and maintain an up-to-date list of devices that are determined by the Secretary to be in shortage in the United States. (2) Contents For each device included on the list under paragraph (1), the Secretary shall include the following information: (A) The category or name of the device in shortage. (B) The name of each manufacturer of such device. (C) The reason for the shortage, as determined by the Secretary, selecting from the following categories: (i) Requirements related to complying with good manufacturing practices. (ii) Regulatory delay. (iii) Shortage or discontinuance of a component or part. (iv) Discontinuance of the manufacture of the device. (v) Delay in shipping of the device. (vi) Delay in sterilization of the device. (vii) Demand increase for the device. (D) The estimated duration of the shortage as determined by the Secretary. (3) Public availability (A) In general Subject to subparagraphs (B) and (C), the Secretary shall make the information in the list under paragraph (1) publicly available. (B) Trade secrets and confidential information Nothing in this subsection shall be construed to alter or amend section 1905 of title 18, United States Code, or section 552(b)(4) of title 5 of such Code. (C) Public health exception The Secretary may elect not to make information collected under this subsection publicly available if the Secretary determines that disclosure of such information would adversely affect the public health (such as by increasing the possibility of hoarding or other disruption of the availability of the device to patients). (h) Rule of construction Nothing in this section shall be construed to affect the authority of the Secretary on the date of enactment of this section to expedite the review of devices under section 515 of the Federal Food, Drug, and Cosmetic Act, section 515B of such Act relating to the priority review program for devices, and section 564 of such Act relating to the emergency use authorization authorities. (i) Definitions In this section: (1) Device The term device (2) Meaningful disruption The term meaningful disruption (A) means a change in production that is reasonably likely to lead to a reduction in the supply of a device by a manufacturer that is more than negligible and affects the ability of the manufacturer to fill orders or meet expected demand for its product; (B) does not include interruptions in manufacturing due to matters such as routine maintenance or insignificant changes in manufacturing so long as the manufacturer expects to resume operations in a reasonable or short period of time; and (C) does not include interruptions in manufacturing of components or raw materials so long as such interruptions do not result in a shortage of finished product and the manufacturer expects to resume operations in a reasonable or short period of time. (3) Shortage The term shortage . 4132. GAO report on intra-agency coordination (a) In general Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report examining the Food and Drug Administration's intra-agency coordination, communication, and decision-making in assessing device shortages and risks associated with the supply of devices, and any efforts by the Food and Drug Administration to mitigate any device shortages or to take corrective actions. (b) Content The report shall include— (1) consideration of— (A) risks of creating, worsening, or extending a shortage of a device associated with violations of current good manufacturing practices; (B) corrective and preventative actions with respect to such violations requested by the Food and Drug Administration; (C) the effects of potential manufacturing disruptions or shut-downs on potential device shortages, which may include the discontinuance of device manufacturing and marketing, or the manufacturing of device components or parts; (D) efforts to prioritize and expedite the review of submissions for devices that the Secretary has determined under section 506J(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356j (E) efforts to prioritize inspections of facilities necessary for approval or clearance of devices described in subparagraph (D); (2) a description of how the Food and Drug Administration proactively coordinates strategies to mitigate the consequences of the violations, slow-downs, and shut-downs described in paragraph (1) across agencies; and (3) an evaluation of changes in relevant Food and Drug Administration practices that such agency has proposed but not yet implemented. (c) Definition In this section, the term device V Emergency use of laboratory developed tests 4141. Emergency use of laboratory developed tests (a) In general For the time in which the public health emergency under section 319 of the Public Health Service Act ( 42 U.S.C. 247d Secretary (b) Criteria Tests described in subsection (a) may be lawfully marketed, during the period described in such subsection, if such test— (1) is developed in a State that has notified the Secretary of its intention to review tests intended to diagnose COVID-19; (2) is developed in a laboratory with a certificate to conduct high-complexity testing pursuant to section 353 of the Public Health Service Act ( 42 U.S.C. 263a (A) is pursuing an emergency use authorization under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 (B) validates such test prior to use; (C) notifies the Secretary of the assay validation; and (D) includes a statement together with the results of the test that reads: This test was developed for use as a part of a response to the public health emergency declared to address the outbreak of COVID-19. This test has not been reviewed by the Food and Drug Administration. (3) is an in vitro diagnostic test for which the developer of such test meets all of the requirements of subparagraphs (A) through (D) of paragraph (2) with respect to the test. (c) Disposition of product Notwithstanding the termination of a declaration under subsection (b) of section 564 of the Federal Food, Drug, and Cosmetic Act, or a revocation under subsection (g) of such section with respect to a product described in subsection (a), the Secretary shall consult with the developer of such in vitro diagnostic test with respect to the appropriate disposition of such test to ensure that authorization of any in vitro diagnostic test under this section shall continue to be effective to provide for continued use of such product to prevent or detect COVID–19. (d) In vitro diagnostic test In this section, the term in vitro diagnostic test in vitro diagnostic product B Access to health care for COVID-19 patients I Coverage of testing and preventive services 4201. Coverage of diagnostic testing for COVID-19 (a) In general A group health plan and a health insurance issuer offering group or individual health insurance coverage (including a grandfathered health plan (as defined in section 1251(e) of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18011(b) (1) An in vitro diagnostic product (as defined in section 809.3(a) of title 21, Code of Federal Regulations) for the detection of SARS–CoV–2 or the diagnosis of the virus that causes COVID–19, and the administration of such an in vitro diagnostic product, that— (A) is approved, cleared, or authorized under section 510(k), 513, 515, or 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(k) (B) is a clinical laboratory service performed in a laboratory (including a public health laboratory) certified to conduct high-complexity testing pursuant to section 353 of the Public Health Service Act ( 42 U.S.C. 253a 21 U.S.C. 360bbb–3 (C) is developed in a State that has notified the Secretary of Health and Human Services of its intention to review tests intended to diagnose COVID-19. (2) Items and services furnished to an individual during health care provider office visits, urgent care center visits, and emergency room visits that result in an order for or administration of an in vitro diagnostic product described in paragraph (1), but only to the extent such items and services relate to the furnishing or administration of such product or to the evaluation of such individual for purposes of determining the need of such individual for such product. 4202. Pricing of diagnostic testing (a) Reimbursement rates A group health plan or a health insurance issuer providing coverage of items and services described in section 201(a) with respect to an enrollee shall reimburse the provider of the diagnostic testing as follows: (1) If the health plan or issuer has a negotiated rate for such service with such provider, such negotiated rate shall apply. (2) If the health plan or issuer does not have a negotiated rate for such service with such provider, such plan or issuer shall reimburse the provider in an amount that equals the cash price for such service as listed by the provider on a public internet website. (b) Requirement to Publicize Cash Price for Diagnostic Testing for COVID-19 (1) In general Each provider of a diagnostic test for COVID-19 shall make public the cash price for such test on a public internet website of such provider. (2) Civil monetary penalties The Secretary of Health and Human Services may impose a civil monetary penalty on any provider of a diagnostic test for COVID-19 that is not in compliance with paragraph (1) and has not completed a corrective action plan to comply with the requirements of such paragraph, in an amount not to exceed $300 per day that the violation is ongoing. 4203. Rapid coverage of preventive services and vaccines for coronavirus (a) In general Notwithstanding 2713(b) of the Public Health Service Act ( 42 U.S.C. 300gg–13 42 U.S.C. 300gg–13(a) (b) Definitions For purposes of this section: (1) Qualifying coronavirus preventive service The term qualifying coronavirus preventive service (A) an evidence-based item or service that has in effect a rating of A B (B) an immunization that has in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention with respect to the individual involved. (2) Specified date The term specified date (3) Health insurance terms In this section, the terms group health plan health insurance issuer group health insurance coverage individual health insurance coverage 42 U.S.C. 300gg–91 II Support for health care providers 4211. Supplemental awards for health centers (a) Supplemental awards Section 330(r) of the Public Health Service Act ( 42 U.S.C. 254b(r) (6) Additional amounts for supplemental awards In addition to any amounts made available pursuant to this subsection, section 402A of this Act, or section 10503 of the Patient Protection and Affordable Care Act, there is authorized to be appropriated, and there is appropriated, out of any monies in the Treasury not otherwise appropriated, $1,320,000,000 for fiscal year 2020 for supplemental awards under subsection (d) for the detection of SARS-CoV-2 or the prevention, diagnosis, and treatment of COVID-19. . (b) Application of provisions Amounts appropriated pursuant to the amendment made by subsection (a) for fiscal year 2020 shall be subject to the requirements contained in Public Law 116–94 42 U.S.C. 254 4212. Allowing permanent direct hire of NDMS health care professionals Section 2812(c)(4) of the Public Health Service Act ( 42 U.S.C. 300hh–11(c)(4) (4) Certain appointments If the Secretary determines that the number of intermittent disaster response personnel within the National Disaster Medical System under this section is insufficient to address a public health emergency or potential public health emergency, the Secretary may appoint candidates directly to personnel positions for intermittent disaster response within such system. The Secretary shall provide updates on the number of vacant or unfilled positions within such system to the congressional committees of jurisdiction each quarter for which this authority is in effect. . 4213. Telehealth network and telehealth resource centers grant programs Section 330I of the Public Health Service Act ( 42 U.S.C. 254c–14 (1) in subsection (d)— (A) in paragraph (1)— (i) in the matter preceding subparagraph (A), by striking projects to demonstrate how telehealth technologies can be used through telehealth networks evidence-based projects that utilize telehealth technologies through telehealth networks (ii) in subparagraph (A)— (I) by striking the quality of access to, and the quality of, (II) by inserting and (iii) by striking subparagraph (B); (iv) by redesignating subparagraph (C) as subparagraph (B); and (v) in subparagraph (B), as so redesignated, by striking and patients and their families, for decisionmaking , patients, and their families (B) in paragraph (2)— (i) by striking demonstrate how telehealth technologies can be used support initiatives that utilize telehealth technologies (ii) by striking , to establish telehealth resource centers (2) in subsection (e), by striking 4 years 5 years (3) in subsection (f)— (A) by striking paragraph (2); (B) in paragraph (1)(B)— (i) by redesignating clauses (i) through (iii) as paragraphs (1) through (3), respectively, and adjusting the margins accordingly; (ii) in paragraph (3), as so redesignated by clause (i), by redesignating subclauses (I) through (XII) as subparagraphs (A) through (L), respectively, and adjusting the margins accordingly; and (iii) by striking (1) Telehealth network grants (B) Telehealth networks (C) in paragraph (3)(I), as so redesignated, by inserting and substance use disorder mental health (4) in subsection (g)(2), by striking or improve and improve (5) by striking subsection (h); (6) by redesignating subsections (i) through (p) as subsection (h) through (o), respectively; (7) in subsection (h), as so redesignated— (A) in paragraph (1)— (i) in subparagraph (B), by striking mental health, public health, long-term care, home care, preventive mental health care, public health services, long-term care, home care, preventive care (ii) in subparagraph (E), by inserting and regional local (iii) by striking subparagraph (F); and (B) in paragraph (2)(A), by striking medically underserved areas or rural areas, medically underserved areas, or (8) in paragraph (2) of subsection (i), as so redesignated, by striking ensure that— ensure that not less than 50 percent of the funds awarded shall be awarded for projects in rural areas. (9) in subsection (j), as so redesignated— (A) in paragraph (1)(B), by striking computer hardware and software, audio and video equipment, computer network equipment, interactive equipment, data terminal equipment, and other (B) in paragraph (2)(F), by striking health care providers and (10) in subsection (k), as so redesignated— (A) in paragraph (2), by striking 40 percent 20 percent (B) in paragraph (3), by striking (such as laying cable or telephone lines, or purchasing or installing microwave towers, satellite dishes, amplifiers, or digital switching equipment) (11) by striking subsections (q) and (r) and inserting the following: (p) Report Not later than 4 years after the date of enactment of the CARES Act ; (12) by redesignating subsection (s) as subsection (q); and (13) in subsection (q), as so redesignated, by striking this section— this section $29,000,000 for each of fiscal years 2021 through 2025. 4214. Rural health care services outreach, rural health network development, and small health care provider quality improvement grant programs Section 330A of the Public Health Service Act ( 42 U.S.C. 254c (1) in subsection (d)(2)— (A) in subparagraph (A), by striking essential basic (B) in subparagraph (B)— (i) in the matter preceding clause (i), by inserting to grants (ii) in clauses (i), (ii), and (iii), by striking to (2) in subsection (e)— (A) in paragraph (1)— (i) by inserting improving and outreach by (ii) by inserting , through community engagement and evidence-based or innovative, evidence-informed models (iii) by striking 3 years 5 years (B) in paragraph (2)— (i) in the matter preceding subparagraph (A), by inserting shall entity (ii) in subparagraph (A), by striking shall be a rural public or rural nonprofit private entity be an entity with demonstrated experience serving, or the capacity to serve, rural underserved populations (iii) in subparagraphs (B) and (C), by striking shall (iv) in subparagraph (B)— (I) in the matter preceding clause (i), by inserting that members (II) in clauses (i) and (ii), by striking that (C) in paragraph (3)(C), by striking the local community or region the rural underserved populations in the local community or region (3) in subsection (f)— (A) in paragraph (1)— (i) in subparagraph (A)— (I) in the matter preceding clause (i), by striking promote, through planning and implementation, the development of integrated health care networks that have combined the functions of the entities participating in the networks plan, develop, and implement integrated health care networks that collaborate (II) in clause (ii), by striking essential health care services basic health care services and associated health outcomes (ii) by amending subparagraph (B) to read as follows: (B) Grant periods The Director may award grants under this subsection for periods of not more than 5 years. ; (B) in paragraph (2)— (i) in the matter preceding subparagraph (A), by inserting shall entity (ii) in subparagraph (A), by striking shall be a rural public or rural nonprofit private entity be an entity with demonstrated experience serving, or the capacity to serve, rural underserved populations (iii) in subparagraph (B)— (I) in the matter preceding clause (i)— (aa) by striking shall (bb) by inserting that participants (II) in clauses (i) and (ii), by striking that (iv) in subparagraph (C), by striking shall (C) in paragraph (3)— (i) by amending clause (iii) of subparagraph (C) to read as follows: (iii) how the rural underserved populations in the local community or region to be served will benefit from and be involved in the development and ongoing operations of the network; ; and (ii) in subparagraph (D), by striking the local community or region the rural underserved populations in the local community or region (4) in subsection (g)— (A) in paragraph (1)— (i) by inserting , including activities related to increasing care coordination, enhancing chronic disease management, and improving patient health outcomes (ii) by striking 3 years 5 years (B) in paragraph (2)— (i) in the matter preceding subparagraph (A), by inserting shall entity (ii) in subparagraphs (A) and (B), by striking shall (iii) in subparagraph (A)(ii), by inserting or regional local (C) in paragraph (3)(D), by striking the local community or region the rural underserved populations in the local community or region (5) in subsection (h)(3), in the matter preceding subparagraph (A), by inserting , as appropriate, the Secretary (6) by amending subsection (i) to read as follows: (i) Report Not later than 4 years after the date of enactment of the CARES Act ; and (7) in subsection (j), by striking $45,000,000 for each of fiscal years 2008 through 2012 $79,500,000 for each of fiscal years 2021 through 2025 4215. United States Public Health Service Modernization (a) Commissioned corps and ready reserve corps Section 203 of the Public Health Service Act ( 42 U.S.C. 204 (1) in subsection (a)(1), by striking a Ready Reserve Corps for service in time of national emergency , for service in time of a public health or national emergency, a Ready Reserve Corps (2) in subsection (c)— (A) in the heading, by striking research Reserve Corps (B) in paragraph (1), by inserting during public health or national emergencies (C) in paragraph (2)— (i) in the matter preceding subparagraph (A), by inserting , consistent with paragraph (1) shall (ii) in subparagraph (C), by inserting during such emergencies members (iii) in subparagraph (D), by inserting , consistent with subparagraph (C) (D) by adding at the end the following: (3) Statutory references to reserve A reference in any Federal statute, except in the case of subsection (b), to the Reserve Corps reserve . (b) Deployment readiness Section 203A(a)(1)(B) of the Public Health Service Act ( 42 U.S.C. 204a(a)(1)(B) Active Reserves Ready Reserve Corps (c) Retirement of commissioned officers Section 211 of the Public Health Service Act ( 42 U.S.C. 212 (1) by striking the Service the Regular Corps (2) in subsection (a)(4), by striking (in the case of an officer in the Reserve Corps) (3) in subsection (c)— (A) in paragraph (1)— (i) by striking or an officer of the Reserve Corps (ii) by inserting or under section 221(a)(19) subsection (a) (B) in paragraph (2), by striking Regular or Reserve Corps Regular Corps or Ready Reserve Corps (4) in subsection (f), by striking the Regular or Reserve Corps of (d) Rights, privileges, etc. of officers and surviving beneficiaries Section 221 of the Public Health Service Act ( 42 U.S.C. 213a (1) in subsection (a), by adding at the end the following: (19) Chapter 1223, Retired Pay for Non-Regular Service. (20) Section 12601, Compensation: Reserve on active duty accepting from any person. (21) Section 12684, Reserves: separation for absence without authority or sentence to imprisonment. ; and (2) in subsection (b)— (A) by striking Secretary of Health, Education, and Welfare or his designee Secretary of Health and Human Services or the designee of such secretary (B) by striking (b) The authority vested (b) (1) The authority vested ; (C) by striking For purposes of (2) For purposes of ; and (D) by adding at the end the following: (3) For purposes of paragraph (19) of subsection (a), the terms Military department Secretary concerned Armed forces . (e) Technical amendments Title II of the Public Health Service Act ( 42 U.S.C. 202 (1) in sections 204 and 207(c), by striking Regular or Reserve Corps Regular Corps or Ready Reserve Corps (2) in section 208(a), by striking Regular and Reserve Corps Regular Corps and Ready Reserve Corps (3) in section 205(c), 206(c), 210, and 219, and in subsections (a), (b), and (d) of section 207, by striking Reserve Corps Ready Reserve Corps 4216. Limitation on liability for volunteer health care professionals during covid-19 emergency response (a) Limitation on liability Except as provided in subsection (b), a health care professional shall not be liable under Federal or State law for any harm caused by an act or omission of the professional in the provision of health care services during the public health emergency declared by the Secretary of Health and Human Services (referred to in this section as the Secretary 42 U.S.C. 247d (1) the professional is providing health care services in response to such public health emergency, as a volunteer; and (2) the act or omission occurs— (A) in the course of providing health care services; (B) in the health care professional’s capacity as a volunteer; (C) in the course of providing health care services that are within the scope of the license, registration, or certification of the volunteer, as defined by the State of licensure, registration, or certification; and (D) in a good faith belief that the individual being treated is in need of health care services. (b) Exceptions Subsection (a) does not apply if— (1) the harm was caused by an act or omission constituting willful or criminal misconduct, gross negligence, reckless misconduct, or a conscious flagrant indifference to the rights or safety of the individual harmed by the health care professional; or (2) the health care professional rendered the health care services under the influence (as determined pursuant to applicable State law) of alcohol or an intoxicating drug. (c) Preemption (1) In general This section preempts the laws of a State or any political subdivision of a State to the extent that such laws are inconsistent with this section, unless such laws provide greater protection from liability. (2) Volunteer Protection Act Protections afforded by this section are in addition to those provided by the Volunteer Protection Act of 1997 ( Public Law 105–19 (d) Definitions In this section— (1) the term harm (2) the term health care professional (3) the term health care services (A) the diagnosis, prevention, or treatment of COVID-19; or (B) the assessment or care of the health of a human being; and (4) the term volunteer (A) includes a payment under any insurance policy or health plan, or under any Federal or State health benefits program; and (B) excludes receipt of items to be used exclusively for rendering health care services in the health care professional’s capacity as a volunteer described in subsection (a)(1). (e) Effective date This section shall take effect upon the date of enactment of this Act, and applies to a claim for harm only if the act or omission that caused such harm occurred on or after the date of enactment. (f) Sunset This section shall be in effect only for the length of the public health emergency declared by the Secretary of Health and Human Services (referred to in this section as the Secretary 42 U.S.C. 247d III Miscellaneous provisions 4221. Confidentiality and disclosure of records relating to substance use disorder (a) Conforming changes relating to substance use disorder Subsections (a) and (h) of section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2 substance abuse substance use disorder (b) Disclosures to covered entities consistent with HIPAA Paragraph (1) of section 543(b) of the Public Health Service Act ( 42 U.S.C. 290dd–2(b) (1) Consent The following shall apply with respect to the contents of any record referred to in subsection (a): (A) Such contents may be used or disclosed in accordance with the prior written consent of the patient with respect to whom such record is maintained. (B) Once prior written consent of the patient has been obtained, such contents may be used or disclosed by a covered entity, business associate, or a program subject to this section for purposes of treatment, payment, and health care operations as permitted by the HIPAA regulations. Any information so disclosed may then be redisclosed in accordance with the HIPAA regulations. Section 13405(c) of the Health Information Technology and Clinical Health Act ( 42 U.S.C. 17935(c) (C) It shall be permissible for a patient’s prior written consent to be given once for all such future uses or disclosures for purposes of treatment, payment, and health care operations, until such time as the patient revokes such consent in writing. (D) Section 13405(a) of the Health Information Technology and Clinical Health Act ( 42 U.S.C. 17935(a) . (c) Disclosures of de-Identified health information to public health authorities Paragraph (2) of section 543(b) of the Public Health Service Act ( 42 U.S.C. 290dd–2(b) (D) To a public health authority, so long as such content meets the standards established in section 164.514(b) of title 45, Code of Federal Regulations (or successor regulations) for creating de-identified information. . (d) Definitions Section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2 (k) Definitions For purposes of this section: (1) Breach The term breach (2) Business associate The term business associate (3) Covered entity The term covered entity (4) Health care operations The term health care operations (5) HIPPA regulations The term HIPAA regulations (6) Payment The term payment (7) Public health authority The term public health authority (8) Treatment The term treatment (9) Unsecured protected health information The term unprotected health information . (e) Use of records in criminal, civil, or administrative investigations, actions, or proceedings Subsection (c) of section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2(c) (c) Use of records in criminal, civil, or administrative contexts Except as otherwise authorized by a court order under subsection (b)(2)(C) or by the consent of the patient, a record referred to in subsection (a), or testimony relaying the information contained therein, may not be disclosed or used in any civil, criminal, administrative, or legislative proceedings conducted by any Federal, State, or local authority, including with respect to the following activities: (1) Such record or testimony shall not be entered into evidence in any criminal prosecution or civil action before a Federal or State court. (2) Such record or testimony shall not form part of the record for decision or otherwise be taken into account in any proceeding before a Federal, State, or local agency. (3) Such record or testimony shall not be used by any Federal, State, or local agency for a law enforcement purpose or to conduct any law enforcement investigation. (4) Such record or testimony shall not be used in any application for a warrant. . (f) Penalties Subsection (f) of section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2 (f) Penalties The provisions of sections 1176 and 1177 of the Social Security Act shall apply to a violation of this section to the extent and in the same manner as such provisions apply to a violation of part C of title XI of such Act. In applying the previous sentence— (1) the reference to this subsection this subsection (including as applied pursuant to section 543(f) of the Public Health Service Act) (2) in subsection (b) of such section 1176— (A) each reference to a penalty imposed under subsection (a) a penalty imposed under subsection (a) (including as applied pursuant to section 543(f) of the Public Health Service Act) (B) each reference to no damages obtained under subsection (d) no damages obtained under subsection (d) (including as applied pursuant to section 543(f) of the Public Health Service Act) . (g) Antidiscrimination Section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2 (i) Antidiscrimination (1) In general No entity shall discriminate against an individual on the basis of information received by such entity pursuant to an inadvertent or intentional disclosure of records, or information contained in records, described in subsection (a) in— (A) admission, access to, or treatment for health care; (B) hiring, firing, or terms of employment, or receipt of worker’s compensation; (C) the sale, rental, or continued rental of housing; (D) access to Federal, State, or local courts; or (E) access to, approval of, or maintenance of social services and benefits provided or funded by Federal, State, or local governments. (2) Recipients of Federal funds No recipient of Federal funds shall discriminate against an individual on the basis of information received by such recipient pursuant to an intentional or inadvertent disclosure of such records or information contained in records described in subsection (a) in affording access to the services provided with such funds. . (h) Notification in case of breach Section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2 (j) Notification in case of breach The provisions of section 13402 of the HITECH Act ( 42 U.S.C. 17932 . (i) Regulations (1) In general The Secretary of Health and Human Services, in consultation with appropriate Federal agencies, shall make such revisions to regulations as may be necessary for implementing and enforcing the amendments made by this section, such that such amendments shall apply with respect to uses and disclosures of information occurring on or after the date that is 12 months after the date of enactment of this Act. (2) Easily understandable notice of privacy practices Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with appropriate legal, clinical, privacy, and civil rights experts, shall update section 164.520 of title 45, Code of Federal Regulations, so that covered entities and entities creating or maintaining the records described in subsection (a) provide notice, written in plain language, of privacy practices regarding patient records referred to in section 543(a) of the Public Health Service Act ( 42 U.S.C. 290dd–2(a) (A) a statement of the patient’s rights, including self-pay patients, with respect to protected health information and a brief description of how the individual may exercise these rights (as required by subsection (b)(1)(iv) of such section 164.520); and (B) a description of each purpose for which the covered entity is permitted or required to use or disclose protected health information without the patient’s written authorization (as required by subsection (b)(2) of such section 164.520). (j) Rules of construction Nothing in this title or the amendments made by this title shall be construed to limit— (1) a patient’s right, as described in section 164.522 of title 45, Code of Federal Regulations, or any successor regulation, to request a restriction on the use or disclosure of a record referred to in section 543(a) of the Public Health Service Act ( 42 U.S.C. 290dd–2(a) (2) a covered entity’s choice, as described in section 164.506 of title 45, Code of Federal Regulations, or any successor regulation, to obtain the consent of the individual to use or disclose a record referred to in such section 543(a) to carry out treatment, payment, or health care operation. (k) Sense of Congress It is the sense of the Congress that— (1) any person treating a patient through a program or activity with respect to which the confidentiality requirements of section 543 of the Public Health Service Act ( 42 U.S.C. 290dd–2 (2) patients have the right to request a restriction on the use or disclosure of a record referred to in section 543(a) of the Public Health Service Act ( 42 U.S.C. 290dd–2(a) (3) covered entities should make every reasonable effort to the extent feasible to comply with a patient’s request for a restriction regarding such use or disclosure; (4) for purposes of applying section 164.501 of title 45, Code of Federal Regulations, the definition of health care operations shall have the meaning given such term in such section, except that clause (v) of paragraph (6) shall not apply; and (5) programs creating records referred to in section 543(a) of the Public Health Service Act ( 42 U.S.C. 290dd–2(a) 4222. Nutrition services (a) Definitions In this section, the terms Assistant Secretary Secretary State agency area agency on aging 42 U.S.C. 3002 (b) Nutrition services transfer criteria During any portion of the COVID-19 public health emergency declared under section 319 of the Public Health Service Act ( 42 U.S.C. 247d 42 U.S.C. 3023(b) 42 U.S.C. 3030d–2 (c ) Home-delivered nutrition services waiver For purposes of State agencies determining the delivery of nutrition services under section 337 of the Older Americans Act of 1965 ( 42 U.S.C. 3030g 42 U.S.C. 247d (d) Dietary guidelines waiver To facilitate implementation of subparts 1 and 2 of part C of title III of the Older Americans Act of 1965 ( 42 U.S.C. 3030d–2 42 U.S.C. 247d 42 U.S.C. 3030g–21(2)(A) 4223. Guidance on protected health information Not later than 180 days after the date of enactment of this Act, the Secretary of Health and Human Services shall issue guidance on the sharing of patients' protected health information pursuant to section 160.103 of title 45, Code of Federal Regulations (or any successor regulations) during the public health emergency declared by the Secretary of Health and Human Services under section 319 of the Public Health Service Act ( 42 U.S.C. 247d 42 U.S.C. 5191(b) 50 U.S.C. 1601 42 U.S.C. 1320d–2 4224. Reauthorization of healthy start program Section 330H of the Public Health Service Act ( 42 U.S.C. 254c–8 (1) in subsection (a)— (A) in paragraph (1), by striking , during fiscal year 2001 and subsequent years, (B) in paragraph (2), by inserting or increasing above the national average areas with high (2) in subsection (b)— (A) in paragraph (1), by striking consumers of project services, public health departments, hospitals, health centers under section 330 participants and former participants of project services, public health departments, hospitals, health centers under section 330, State substance abuse agencies (B) in paragraph (2)— (i) in subparagraph (A), by striking such as low birthweight including poor birth outcomes (such as low birthweight and preterm birth) and social determinants of health (ii) by redesignating subparagraph (B) as subparagraph (C); (iii) by inserting after subparagraph (A), the following: (B) Communities with— (i) high rates of infant mortality or poor perinatal outcomes; or (ii) high rates of infant mortality or poor perinatal outcomes in specific subpopulations within the community. ; and (iv) in subparagraph (C) (as so redesignated)— (I) by redesignating clauses (i) and (ii) as clauses (ii) and (iii), respectively; (II) by inserting before clause (ii) (as so redesignated) the following: (i) collaboration with the local community in the development of the project; ; (III) in clause (ii) (as so redesignated), by striking and (IV) in clause (iii) (as so redesignated), by striking the period and inserting ; and (V) by adding at the end the following: (iv) the use and collection of data demonstrating the effectiveness of such program in decreasing infant mortality rates and improving perinatal outcomes, as applicable, or the process by which new applicants plan to collect this data. ; (3) in subsection (c)— (A) by striking Recipients of grants (1) In general Recipients of grants ; and (B) by adding at the end the following: (2) Other programs The Secretary shall ensure coordination of the program carried out pursuant to this section with other programs and activities related to the reduction of the rate of infant mortality and improved perinatal and infant health outcomes supported by the Department. ; (4) in subsection (e)— (A) in paragraph (1), by striking appropriated— appropriated $122,500,000 for each of fiscal years 2020 through 2024. (B) in paragraph (2)(B), by adding at the end the following: “Evaluations may also include, to the extent practicable, information related to— (i) progress toward achieving any grant metrics or outcomes related to reducing infant mortality rates, improving perinatal outcomes, or reducing the disparity in health status; (ii) recommendations on potential improvements that may assist with addressing gaps, as applicable and appropriate; and (iii) the extent to which the grantee coordinated with the community in which the grantee is located in the development of the project and delivery of services, including with respect to technical assistance and mentorship programs. ; and (5) by adding at the end the following: (f) GAO report (1) In general Not later than 4 years after the date of the enactment of this subsection, the Comptroller General of the United States shall conduct an independent evaluation, and submit to the appropriate Committees of Congress a report, concerning the Healthy Start program under this section. (2) Evaluation In conducting the evaluation under paragraph (1), the Comptroller General shall consider, as applicable and appropriate, information from the evaluations under subsection (e)(2)(B). (3) Report The report described in paragraph (1) shall review, assess, and provide recommendations, as appropriate, on the following: (A) The allocation of Healthy Start program grants by the Health Resources and Services Administration, including considerations made by such Administration regarding disparities in infant mortality or perinatal outcomes among urban and rural areas in making such awards. (B) Trends in the progress made toward meeting the evaluation criteria pursuant to subsection (e)(2)(B), including programs which decrease infant mortality rates and improve perinatal outcomes, programs that have not decreased infant mortality rates or improved perinatal outcomes, and programs that have made an impact on disparities in infant mortality or perinatal outcomes. (C) The ability of grantees to improve health outcomes for project participants, promote the awareness of the Healthy Start program services, incorporate and promote family participation, facilitate coordination with the community in which the grantee is located, and increase grantee accountability through quality improvement, performance monitoring, evaluation, and the effect such metrics may have toward decreasing the rate of infant mortality and improving perinatal outcomes. (D) The extent to which such Federal programs are coordinated across agencies and the identification of opportunities for improved coordination in such Federal programs and activities. . C Innovation 4301. Removing the cap on OTA Section 319L(c)(5)(A)(ii) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(5)(A)(ii)) is amended to read as follows: (ii) Limitations on authority To the maximum extent practicable, competitive procedures shall be used when entering into transactions to carry out projects under this subsection. . 4302. Extending the priority review program for agents that present national security threats Section 565A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–4a 4303. Priority zoonotic animal drugs Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 512A. Priority zoonotic animal drugs (a) In general The Secretary shall, at the request of the sponsor intending to submit an application for approval of a new animal drug under section 512(b)(1) or an application for conditional approval of a new animal drug under section 571, expedite the development and review of such new animal drug if preliminary clinical evidence indicates that the new animal drug, alone or in combination with 1 or more other animal drugs, has the potential to prevent or treat a zoonotic disease in animals, including a vector borne-disease, that has the potential to cause serious adverse health consequences for, or serious or life-threatening diseases in, humans. (b) Request for designation The sponsor of a new animal drug may request the Secretary to designate a new animal drug described in subsection (a) as a priority zoonotic animal drug. A request for the designation may be made concurrently with, or at any time after, the opening of an investigational new animal drug file under section 512(j) or the filing of an application under section 512(b)(1) or 571. (c) Designation (1) In general Not later than 60 calendar days after the receipt of a request under subsection (b), the Secretary shall determine whether the new animal drug that is the subject of the request meets the criteria described in subsection (a). If the Secretary determines that the new animal drug meets the criteria, the Secretary shall designate the new animal drug as a priority zoonotic animal drug and shall take such actions as are appropriate to expedite the development and review of the application for approval or conditional approval of such new animal drug. (2) Actions The actions to expedite the development and review of an application under paragraph (1) may include, as appropriate— (A) taking steps to ensure that the design of clinical trials is as efficient as practicable, when scientifically appropriate, such as by utilizing novel trial designs or drug development tools (including biomarkers) that may reduce the number of animals needed for studies; (B) providing timely advice to, and interactive communication with, the sponsor (which may include meetings with the sponsor and review team) regarding the development of the new animal drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; (C) involving senior managers and review staff with experience in zoonotic or vector-borne disease to facilitate collaborative, cross-disciplinary review, including, as appropriate, across agency centers; and (D) implementing additional administrative or process enhancements, as necessary, to facilitate an efficient review and development program. . D Finance Committee 4401. Exemption for telehealth services (a) In general Paragraph (2) of section 223(c) (E) Safe harbor for absence of deductible for telehealth In the case of plan years beginning on or before December 31, 2021, a plan shall not fail to be treated as a high deductible health plan by reason of failing to have a deductible for telehealth and other remote care services. . (b) Certain coverage disregarded Clause (ii) of section 223(c)(1)(B) or long-term care long-term care, or (in the case of plan years beginning on or before December 31, 2021) telehealth and other remote care (c) Effective date The amendments made by this section shall take effect on the date of the enactment of this Act. 4402. Inclusion of certain over-the-counter medical products as qualified medical expenses (a) HSAs Section 223(d)(2) (1) by striking the last sentence of subparagraph (A) and inserting the following: For purposes of this subparagraph, amounts paid for menstrual care products shall be treated as paid for medical care. (2) by adding at the end the following new subparagraph: (D) Menstrual care product For purposes of this paragraph, the term menstrual care product . (b) Archer MSAs Section 220(d)(2)(A) of such Code is amended by striking the last sentence and inserting the following: For purposes of this subparagraph, amounts paid for menstrual care products (as defined in section 223(d)(2)(D)) shall be treated as paid for medical care. (c) Health flexible spending arrangements and health reimbursement arrangements Section 106 of such Code is amended by striking subsection (f) and inserting the following new subsection: (f) Reimbursements for menstrual care products For purposes of this section and section 105, expenses incurred for menstrual care products (as defined in section 223(d)(2)(D)) shall be treated as incurred for medical care. . (d) Effective dates (1) Distributions from savings accounts The amendment made by subsections (a) and (b) shall apply to amounts paid after December 31, 2019. (2) Reimbursements The amendment made by subsection (c) shall apply to expenses incurred after December 31, 2019. 4403. Treatment of direct primary care service arrangements (a) In general Section 223(c)(1) (D) Treatment of direct primary care service arrangements (i) In general A direct primary care service arrangement shall not be treated as a health plan for purposes of subparagraph (A)(ii). (ii) Direct primary care service arrangement For purposes of this paragraph— (I) In general The term direct primary care service arrangement (II) Limitation With respect to any individual for any month, such term shall not include any arrangement if the aggregate fees for all direct primary care service arrangements (determined without regard to this subclause) with respect to such individual for such month exceed $150 (twice such dollar amount in the case of an individual with any direct primary care service arrangement (as so determined) that covers more than one individual). (iii) Certain services specifically excluded from treatment as primary care services For purposes of this paragraph, the term primary care services (I) procedures that require the use of general anesthesia, and (II) laboratory services not typically administered in an ambulatory primary care setting. The Secretary, after consultation with the Secretary of Health and Human Services, shall issue regulations or other guidance regarding the application of this clause. . (b) Direct primary care service arrangement fees treated as medical expenses Section 223(d)(2)(C) or , or (v) any direct primary care service arrangement. . (c) Inflation adjustment Section 223(g)(1) of such Code is amended— (1) by inserting , (c)(1)(D)(ii)(II), (b)(2), (2) in subparagraph (B), by inserting and (iii) clause (ii) and , and (iii) in the case of the dollar amount in subsection (c)(1)(D)(ii)(II) for taxable years beginning in calendar years after 2020, calendar year 2019 ”. (d) Reporting of direct primary care service arrangement fees on w–2 Section 6051(a) of such Code is amended by striking and , and (18) in the case of a direct primary care service arrangement (as defined in section 223(c)(1)(D)(ii)) which is provided in connection with employment, the aggregate fees for such arrangement for such employee. . (e) Effective date The amendments made by this section shall apply to months beginning after December 31, 2019, in taxable years ending after such date. 4404. Increasing Medicare telehealth flexibilities during emergency period Section 1135 of the Social Security Act ( 42 U.S.C. 1320b–5 (1) in subsection (b)(8), by striking to an individual by a qualified provider (as defined in subsection (g)(3)) , the requirements of section 1834(m). (2) in subsection (g), by striking paragraph (3). 4405. Enhancing Medicare telehealth services for Federally qualified health centers and rural health clinics during emergency period Section 1834(m) of the Social Security Act ( 42 U.S.C. 1395m(m) (1) in the first sentence of paragraph (1), by striking The Secretary Subject to paragraph (8), the Secretary (2) in paragraph (2)(A), by striking The Secretary Subject to paragraph (8), the Secretary (3) in paragraph (4)— (A) in subparagraph (A), by striking The term Subject to paragraph (8), the term (B) in subparagraph (F)(i), by striking The term Subject to paragraph (8), the term (4) by adding at the end the following new paragraph: (8) Enhancing telehealth services for Federally qualified health centers and rural health clinics during emergency period (A) In general During the emergency period described in section 1135(g)(1)(B)— (i) the Secretary shall pay for telehealth services that are furnished via a telecommunications system by a Federally qualified health center or a rural health clinic to an eligible telehealth individual enrolled under this part notwithstanding that the Federally qualified health center or rural clinic providing the telehealth service is not at the same location as the beneficiary; (ii) the amount of payment to a Federally qualified health center or rural health clinic that serves as a distant site for such a telehealth service shall be determined under subparagraph (B); and (iii) for purposes of this subsection— (I) the term distant site (II) the term telehealth services (B) Special payment rule The Secretary shall develop and implement payment methods that apply under this subsection to a Federally qualified health center or rural health clinic that serves as a distant site that furnishes a telehealth service to an eligible telehealth individual during such emergency period. Such payment methods shall be based on a composite rate that is similar to the payment that applies to payment for comparable telehealth services under the physician fee schedule under section 1848. Notwithstanding any other provision of law, the Secretary may implement such payment methods through program instruction or otherwise. . 4406. Temporary waiver of requirement for face-to-face visits between home dialysis patients and physicians Section 1881(b)(3)(B) of the Social Security Act ( 42 U.S.C. 1395rr(b)(3)(B) (1) in clause (i), by striking clause (ii) clauses (ii) and (iii) (2) in clause (ii), in the matter preceding subclause (I), by striking Clause (i) Except as provided in clause (iii), clause (i) (3) by adding at the end the following new clause: (iii) The Secretary may waive the provisions of clause (ii) during the emergency period described in section 1135(g)(1)(B). . 4407. Improving care planning for Medicare home health services (a) Part A provisions Section 1814(a) of the Social Security Act ( 42 U.S.C. 1395f(a) (1) in paragraph (2)— (A) in the matter preceding subparagraph (A), by inserting , a nurse practitioner or clinical nurse specialist (as such terms are defined in section 1861(aa)(5)) who is working in accordance with State law, or a physician assistant (as defined in section 1861(aa)(5)) under the supervision of a physician, who is in the case of services described in subparagraph (C), a physician (B) in subparagraph (C)— (i) by inserting , a nurse practitioner, a clinical nurse specialist, or a physician assistant (as the case may be) physician (ii) by striking , and, in the case of a certification made by a physician face-to-face encounter , and, in the case of a certification made by a physician after January 1, 2010, or by a nurse practitioner, clinical nurse specialist, or physician assistant (as the case may be) after a date specified by the Secretary (but in no case later than the date that is 6 months after the date of the enactment of the CARES Act (2) in the third sentence— (A) by striking physician certification certification (B) by inserting (or in the case of regulations to implement the amendments made by section 4407 of the CARES Act 1981 (C) by striking a physician who a physician, nurse practitioner, clinical nurse specialist, certified nurse-midwife, or physician assistant who (3) in the fourth sentence, by inserting , nurse practitioner, clinical nurse specialist, certified nurse-midwife, or physician assistant physician (4) in the fifth sentence— (A) by inserting or no later than six months after the enactment of this legislation for purposes of documentation for certification and recertification made under paragraph (2) by a nurse practitioner, clinical nurse specialist, certified nurse-midwife, or physician assistant, (B) by inserting , nurse practitioner, clinical nurse specialist, certified nurse-midwife, or physician assistant of the physician (b) Part B provisions Section 1835(a) of the Social Security Act ( 42 U.S.C. 1395n(a) (1) in paragraph (2)— (A) in the matter preceding subparagraph (A), by inserting , a nurse practitioner or clinical nurse specialist (as those terms are defined in section 1861(aa)(5)) who is working in accordance with State law, or a physician assistant (as defined in section 1861(aa)(5)) under the supervision of a physician, who is in the case of services described in subparagraph (C), a physician (B) in subparagraph (A)— (i) in each of clauses (ii) and (iii) of subparagraph (A) by inserting , a nurse practitioner, a clinical nurse specialist, or a physician assistant (as the case may be) physician (ii) in clause (iv), by striking after January 1, 2010 face-to-face encounter made by a physician after January 1, 2010, or by a nurse practitioner, clinical nurse specialist, or physician assistant (as the case may be) after a date specified by the Secretary (but in no case later than the date that is 6 months after the date of the enactment of the CARES Act (2) in the third sentence, by inserting , nurse practitioner, clinical nurse specialist, or physician assistant (as the case may be) (3) in the fourth sentence— (A) by striking physician certification certification (B) by inserting (or in the case of regulations to implement the amendments made by section 4407 of the CARES Act 1981 (C) by striking a physician who a physician, nurse practitioner, clinical nurse specialist, or physician assistant who (4) in the fifth sentence, by inserting , nurse practitioner, clinical nurse specialist, or physician assistant physician (5) in the sixth sentence— (A) by inserting or no later than six months after the enactment of this legislation for purposes of documentation for certification and recerification made under paragraph (2) by a nurse practitioner, clinical nurse specialist, certified nurse-midwife, or physician assistant, January 1, 2019 (B) by inserting , nurse practitioner, clinical nurse specialist, certified nurse-midwife, or physician assistant of the physician (c) Definition provisions (1) Home health services Section 1861(m) of the Social Security Act ( 42 U.S.C. 1395x(m) (A) in the matter preceding paragraph (1)— (i) by inserting , a nurse practitioner or a clinical nurse specialist (as those terms are defined in subsection (aa)(5)), or a physician assistant (as defined in subsection (aa)(5)) physician (ii) by inserting , a nurse practitioner, a clinical nurse specialist, or a physician assistant physician (B) in paragraph (3), by inserting , a nurse practitioner, a clinical nurse specialist, or a physician assistant physician (2) Home health agency Section 1861(o)(2) of the Social Security Act ( 42 U.S.C. 1395x(o)(2) (A) by inserting , nurse practitioners or clinical nurse specialists (as those terms are defined in subsection (aa)(5)), certified nurse-midwives (as defined in subsection (gg)), or physician assistants (as defined in subsection (aa)(5)) physicians (B) by inserting , nurse practitioner, clinical nurse specialist, certified nurse-midwife, physician assistant, physician (3) Covered osteoporosis drug Section 1861(kk)(1) of the Social Security Act ( 42 U.S.C. 1395x(kk)(1) , nurse practitioner or clinical nurse specialist (as those terms are defined in subsection (aa)(5)), certified nurse-midwive (as defined in subsection (gg)), or physician assistant (as defined in subsection 1820(aa)(5)) attending physician (d) Home health prospective payment system provisions Section 1895 of the Social Security Act ( 42 U.S.C. 1395fff (1) in subsection (c)(1)— (A) by striking (provided under section 1842(r)) (B) by inserting the 1 nurse practitioner or clinical nurse specialist (as those terms are defined in section 1861(aa)(5)), or the physician assistant (as defined in section 1861(aa)(5)) physician (2) in subsection (e)— (A) in paragraph (1)(A), by inserting or a nurse practitioner or clinical nurse specialist (as those terms are defined in section 1861(aa)(5)) physician (B) in paragraph (2)— (i) in the heading, by striking Physician certification Rule of construction regarding requirement for certification (ii) by striking physician (e) Application to Medicaid The amendments made under this section shall apply under title XIX of the Social Security Act in the same manner and to the same extent as such requirements apply under title XVIII of such Act or regulations promulgated thereunder. (f) Effective date The Secretary of Health and Human Services shall prescribe regulations to apply the amendments made by this section to items and services furnished, which shall become effective no later than six months after the enactment of this legislation. The Secretary shall promulgate an interim final rule if necessary, to comply with the required effective date. 4408. Adjustment of sequestration (a) Temporary suspension of Medicare sequestration During the period beginning on May 1, 2020 and ending on December 31, 2020, the Medicare programs under title XVIII of the Social Security Act ( 42 U.S.C. 1395 (b) Extension of direct spending reductions through fiscal year 2030 Section 251A(6) of the Balanced Budget and Emergency Deficit Control Act of 1985 ( 2 U.S.C. 901a(6) (1) in subparagraph (B), in the matter preceding clause (i), by striking through 2029 through 2030 (2) in subparagraph (C), in the matter preceding clause (i), by striking fiscal year 2029 fiscal year 2030 4409. Medicare hospital inpatient prospective payment system add-on payment for covid–19 patients during emergency period (a) In general Section 1886(d)(4)(C) of the Social Security Act ( 42 U.S.C. 1395ww(d)(4)(C) (iv) (I) For discharges occurring during the emergency period described in section 1135(g)(1)(B), in the case of a discharge that has a principal or secondary diagnosis of COVID–19, the Secretary shall increase the weighting factor for each diagnosis-related group (with such a principal or secondary diagnosis) by 15 percent. (II) Any adjustment under subclause (I) shall not be taken into account in applying budget neutrality under clause (iii). . (b) Implementation Notwithstanding any other provision of law, the Secretary may implement the amendment made by subsection (a) by program instruction or otherwise. 4410. Revising payment rates for durable medical equipment under the Medicare program through duration of emergency period (a) Rural and noncontiguous areas The Secretary of Health and Human Services shall implement section 414.210(g)(9)(iii) of title 42, Code of Federal Regulations (or any successor regulation), to apply the transition rule described in such section to all applicable items and services furnished in rural areas and noncontiguous areas (as such terms are defined for purposes of such section) as planned through December 31, 2020, and through the duration of the emergency period described in section 1135(g)(1)(B) of the Social Security Act ( 42 U.S.C. 1320b–5(g)(1)(B) (b) Areas other than rural and noncontiguous areas With respect to items and services furnished on or after the date that is 30 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall apply section 414.210(g)(9)(iv) of title 42, Code of Federal Regulations (or any successor regulation), as if the reference to dates of service from June 1, 2018 through December 31, 2020, based on the fee schedule amount for the area is equal to 100 percent of the adjusted payment amount established under this section dates of service from March 6, 2020, through the remainder of the duration of the emergency period described in section 1135(g)(1)(B) of the Social Security Act ( 42 U.S.C. 1320b–5(g)(1)(B) 4411. Providing home and community-based services in acute care hospitals Section 1902(h) of the Social Security Act ( 42 U.S.C. 1396a(h) (1) by inserting (1) (h) (2) by inserting , home and community-based services provided under subsection (c), (d), or (i) of section 1915 or under a waiver under section 1115, self-directed personal assistance services provided pursuant to a written plan of care under section 1915(j), and home and community-based attendant services and supports under section 1915(k) (3) by adding at the end the following: (2) Nothing in this title, title XVIII, or title XI shall be construed as prohibiting receipt of any care or services specified in paragraph (1) in an acute care hospital that are— (A) identified in an individual’s person-centered plan of services and supports (or comparable plan of care); (B) provided to meet needs of the individual that are not met through the provision of hospital services; (C) not a substitute for services that the hospital is obligated to provide through its conditions of participation or under Federal or State law; and (D) designed to ensure smooth transitions between acute care settings and home and community-based settings, and to preserve the individual’s functions. . 4412. Treatment of technology-enabled collaborative learning and capacity building models as medical assistance Section 1915 of the Social Security Act ( 42 U.S.C. 1396n (m) Technology-enabled collaborative learning and capacity building models (1) In general A State may provide, as medical assistance, a technology-enabled collaborative learning and capacity building model used by a provider participating under the State plan (or a waiver of such plan) without regard to the requirements of section 1902(a)(1) (relating to statewideness), section 1902(a)(10)(B) (relating to comparability), and section 1902(a)(23) (relating to freedom of choice of providers). (2) Requirements A State shall be eligible for Federal financial assistance for providing such medical assistance under the following conditions: (A) A participating provider uses the technology-enabled collaborative learning and capacity building model to train health professionals (which may include medical students) in protocols for responding to a public health emergency during an emergency period, including any period relating to an outbreak of coronavirus disease 2019 (COVID–19). (B) In accordance with section 1902(a)(25), there are no other third parties liable to pay for the use of such model by a participating provider, including as reimbursement under a medical, social, educational, or other program. (C) The State allocates the costs of any part of the use such model which is reimbursable under another federally funded program in accordance with OMB Circular A–87 (or any related or successor guidance or regulations regarding allocation of costs among federally funded programs) under an approved cost allocation program. (3) Nonapplication of time limits Subsection (h) shall not apply to the provision of medical assistance for technology-enabled collaborative learning and capacity building models under this subsection. (4) Definitions In this subsection: (A) Emergency period The term emergency period (B) Technology-enabled collaborative learning and capacity building model The term technology-enabled collaborative learning and capacity building model Public Law 114–270 . 4413. Encouraging the development and use of DISARM antimicrobial drugs (a) Additional payment for DISARM antimicrobial drugs under Medicare (1) In general Section 1886(d)(5) of the Social Security Act ( 42 U.S.C. 1395ww(d)(5) (M) (i) (I) In the case of discharges occurring on or after October 1, 2021, and before October 1, 2026, subject to subclause (II), the Secretary shall, after notice and opportunity for public comment (in the publications required by subsection (e)(5) for a fiscal year or otherwise), provide for an additional payment under a mechanism (separate from the mechanism established under subparagraph (K)), with respect to such discharges involving any DISARM antimicrobial drug, in an amount equal to— (aa) the amount payable under section 1847A for such drug during the calendar quarter in which the discharge occurred; or (bb) if no amount for such drug is determined under section 1847A, an amount to be determined by the Secretary in a manner similar to the manner in which payment amounts are determined under section 1847A based on information submitted by the manufacturer or sponsor of such drug (as required under clause (v)). (II) In determining the amount payable under section 1847A for purposes of items (aa) and (bb) of subclause (I), subparagraphs (A) and (B) of subsection (b)(1) of such section shall be applied by substituting 100 percent 106 percent 0 percent 6 percent (ii) For purposes of this subparagraph, a DISARM antimicrobial drug is— (I) a drug— (aa) that— (AA) is approved by the Food and Drug Administration; (BB) is designated by the Food and Drug Administration as a qualified infectious disease product under subsection (d) of section 505E of the Federal Food, Drug, and Cosmetic Act; and (CC) has received an extension of its exclusivity period pursuant to subsection (a) of such section; and (bb) that has been designated by the Secretary pursuant to the process established under clause (iv)(I)(bb); or (II) an antibacterial or antifungal biological product— (aa) that is licensed for use, or an antibacterial or antifungal biological product for which an indication is first licensed for use, by the Food and Drug Administration on or after June 5, 2014, under section 351(a) of the Public Health Service Act for human use to treat serious or life-threatening infections, as determined by the Food and Drug Administration, including those caused by, or likely to be caused by— (AA) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens; or (BB) a qualifying pathogen (as defined under section 505E(f) of the Federal Food, Drug, and Cosmetic Act); and (bb) has been designated by the Secretary pursuant to the process established under clause (iv)(I)(bb). (iii) The mechanism established pursuant to clause (i) shall provide that the additional payment under clause (i) shall— (I) with respect to a discharge, only be made to a subsection (d) hospital that, as determined by the Secretary— (aa) is participating in the National Healthcare Safety Network Antimicrobial Use and Resistance Module of the Centers for Disease Control and Prevention or a similar reporting program, as specified by the Secretary, relating to antimicrobial drugs; and (bb) has an antimicrobial stewardship program that aligns with the Core Elements of Hospital Antibiotic Stewardship Programs of the Centers for Disease Control and Prevention or the Antimicrobial Stewardship Standard set by the Joint Commission; and (II) apply to discharges occurring on or after October 1 of the year in which the drug or biological product is designated by the Secretary as a DISARM antimicrobial drug. (iv) (I) The mechanism established pursuant to clause (i) shall provide for a process for— (aa) a manufacturer or sponsor of a drug or biological product to request the Secretary to designate the drug or biological product as a DISARM antimicrobial drug; and (bb) the designation by the Secretary of drugs and biological products as DISARM antimicrobial drugs. (II) A designation of a drug or biological product as a DISARM antimicrobial drug may be revoked by the Secretary if the Secretary determines that— (aa) the drug or biological product no longer meets the requirements for a DISARM antimicrobial drug under clause (ii); (bb) the request for such designation contained an untrue statement of material fact; or (cc) clinical or other information that was not available to the Secretary at the time such designation was made shows that— (AA) such drug or biological product is unsafe for use or not shown to be safe for use for individuals who are entitled to benefits under part A; or (BB) an alternative to such drug or biological product is an advance that substantially improves the diagnosis or treatment of such individuals. (III) Not later than October 1, 2021, and annually thereafter through October 1, 2025, the Secretary shall publish in the Federal Register a list of the DISARM antimicrobial drugs designated under this subparagraph pursuant to the process established under clause (iv)(I)(bb). (v) (I) For purposes of determining additional payment amounts under clause (i), a manufacturer or sponsor of a drug or biological product that submits a request described in clause (iv)(I)(aa) shall submit to the Secretary information described in section 1927(b)(3)(A)(iii). (II) The penalties for failure to provide timely information under clause (i) of subparagraph (C) of section 1927(b)(3) and for providing false information under clause (ii) of such subparagraph shall apply to manufacturers and sponsors of a drug or biological product under this section with respect to information under subclause (I) in the same manner as such penalties apply to manufacturers under such clauses with respect to information under subparagraph (A) of such section. (vi) The mechanism established pursuant to clause (i) shall provide that— (I) except as provided in subclause (II), no additional payment shall be made under this subparagraph for discharges involving a DISARM antimicrobial drug if any additional payments have been made for discharges involving such drug as a new medical service or technology under subparagraph (K); (II) additional payments may be made under this subparagraph for discharges involving a DISARM antimicrobial drug if any additional payments have been made for discharges occurring prior to the date of enactment of this subparagraph involving such drug as a new medical service or technology under subparagraph (K); and (III) no additional payment shall be made under subparagraph (K) for discharges involving a DISARM antimicrobial drug as a new medical service or technology if any additional payments for discharges involving such drug have been made under this subparagraph. . (2) Conforming amendment Section 1886(d)(5)(K)(ii)(III) of the Social Security Act ( 42 U.S.C. 1395ww(d)(5)(K)(ii)(III) provide subject to subparagraph (M)(vi), provide (b) Study and reports on removing barriers to the development of DISARM antimicrobial drugs (1) Study The Comptroller General of the United States (in this subsection referred to as the Comptroller General (A) identify and examine the barriers that prevent the development of DISARM antimicrobial drugs (as defined in section 1886(d)(5)(M)(ii) of the Social Security Act, as added by subsection (a)); and (B) develop recommendations for actions to be taken in order to overcome any barriers identified under subparagraph (A). (2) Report October 1, 2025, the Comptroller General shall submit to Congress a report containing the preliminary results of the study conducted under paragraph (1), together with recommendations for such legislation and administrative action as the Comptroller General determines appropriate. 4414. Novel medical products (a) Expedited coding of novel medical products Section 1174(b)(2)(B) of the Social Security Act ( 42 U.S.C. 1320d–3(b)(2)(B) (iii) Expedited coding of novel medical products (I) In general Notwithstanding paragraph (1), in the case of a novel medical product (as defined in clause (iv)), the Secretary shall make modifications to the HCPCS code set at least once every quarter. (II) Request Upon the written confidential request of a manufacturer of a novel medical product, the Secretary shall make a determination whether to assign a HCPCS code to such product. Such request may occur on or after the date on which the product receives a designation as a breakthrough therapy under section 506(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(a) 21 U.S.C. 360e–3 21 U.S.C. 356(g) (III) Deadline for determination; notification The Secretary shall— (aa) not later than 180 calendar days after receiving the request of a manufacturer under subclause (II), make a determination under such subclause with respect to the request; and (bb) not later than 30 calendar days after making such determination, notify the manufacturer of the determination. (IV) Monitoring utilization and outcomes A HCPCS code assigned under this clause shall allow for the reliable monitoring of utilization and outcomes of the novel medical product as described in clause (vi). (V) Effective date of code assignment If the Secretary makes a determination to assign a HCPCS code to a product under subclause (II), such code— (aa) may be assigned within the first quarter after the manufacturer files, with respect to such product, a new drug application under section 505(b) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b) 42 U.S.C. 262(a) 21 U.S.C. 360e(c) 21 U.S.C. 360k 21 U.S.C. 360c(f)(2) (bb) may not take effect before the date the product is approved, cleared, or licensed by the Food and Drug Administration. (VI) Trade secrets and confidential information No information submitted under subclause (II) shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code. (iv) Novel medical product defined For purposes of this subparagraph, the term novel medical product (I) that has not been assigned a HCPCS code; and (II) that has been designated as a breakthrough therapy under section 506(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(a) 21 U.S.C. 360e–3 21 U.S.C. 356(g) (v) HCPCS defined For purposes of this subparagraph, the term HCPCS (vi) Inpatient products The Secretary shall establish a code modifier within the hospital inpatient prospective payment system under section 1886(d) to track the utilization and outcomes of novel medical products that are assigned a HCPCS code pursuant to the expedited coding process under clause (iii) and are furnished by hospitals in inpatient settings. . (b) Coverage determinations for novel medical products Section 1862(l) of the Social Security Act ( 42 U.S.C. 1395y(l) (7) Coverage pathway for novel medical products (A) In general The Secretary shall facilitate an efficient coverage pathway to expedite a national coverage decision for coverage with evidence development process under this title for novel medical products described in subparagraph (D). The Secretary shall review such novel medical products for the coverage process on an expedited basis, beginning as soon as the Secretary assigns a HCPCS code to the product under clause (iii)(V)(aa) of section 1174(b)(2)(B). (B) Determination of coverage with evidence development Such coverage pathway shall include, with respect to such novel medical products, if the Secretary determines coverage with evidence development is appropriate, issuance of a national coverage determination of coverage with evidence development for a period up to, but not to exceed, 4 years from the date of such determination. (C) Modernizing payment options for novel medical products Not later than 4 years after issuing such national coverage determination, the Secretary shall submit to Congress and to the manufacturer of the novel medical product a report providing options for alternative payment models under this title for the novel medical product or class of such products, which may include the utilization of existing models in the commercial health insurance market. Such report shall include any recommendations for legislation and administrative action as the Secretary determines appropriate to facilitate such payment arrangements. (D) Novel medical products described For purposes of this paragraph, a novel medical product described in this subparagraph is a novel medical product, as defined in clause (iv) of section 1174(b)(2)(B), that is assigned a HCPCS code pursuant to the expedited coding process under clause (iii) of such section. (E) Clarification Nothing in this paragraph shall prevent the Secretary from issuing a noncoverage or a national coverage determination for a novel medical product. . (c) Enhancing coordination with the Food and Drug Administration (1) Public Meeting (A) In general Not later than 12 months after the date of the enactment of this Act, the Secretary shall convene a public meeting for the purposes of discussing and providing input on improvements to coordination between the Food and Drug Administration and the Centers for Medicare & Medicaid Services in preparing for the availability of novel medical products (as defined in section 1174(b)(2)(B)(iv) of the Social Security Act, as added by subsection (a)) on the market in the United States. (B) Attendees The public meeting shall include— (i) representatives of relevant Federal agencies, including representatives from each of the medical product centers within the Food and Drug Administration and representatives from the coding, coverage, and payment offices within the Centers for Medicare & Medicaid Services; (ii) stakeholders with expertise in the research and development of novel medical products, including manufacturers of such products; (iii) representatives of commercial health insurance payers; (iv) stakeholders with expertise in the administration and use of novel medical products, including physicians; and (v) stakeholders representing patients and with expertise in the utilization of patient experience data in medical product development. (C) Topics The public meeting shall include a discussion of— (i) the status of the drug and medical device development pipeline related to the availability of novel medical products; (ii) the anticipated expertise necessary to review the safety and effectiveness of such products at the Food and Drug Administration and current gaps in such expertise, if any; (iii) the expertise necessary to make coding, coverage, and payment decisions with respect to such products within the Centers for Medicare & Medicaid Services, and current gaps in such expertise, if any; (iv) trends in the differences in the data necessary to determine the safety and effectiveness of a novel medical product and the data necessary to determine whether a novel medical product meets the reasonable and necessary requirements for coverage and payment under title XVIII of the Social Security Act pursuant to section 1862(a)(1)(A) of such Act ( 42 U.S.C. 1395y(a)(1)(A) (v) the availability of information for sponsors of such novel medical products to meet each of those requirements; and (vi) the coordination of information related to significant clinical improvement over existing therapies for patients between the Food and Drug Administration and the Centers for Medicare & Medicaid Services with respect to novel medical products. (D) Trade secrets and confidential information No information discussed as a part of the public meeting under this paragraph shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code. (2) Improving transparency of criteria for Medicare coverage (A) Updating guidance Not later than 18 months after the public meeting under paragraph (1), the Secretary of Health and Human Services shall update the final guidance entitled National Coverage Determinations with Data Collection as a Condition of Coverage: Coverage with Evidence Development (B) Finalizing updated guidance Not later than 12 months after issuing draft guidance under subparagraph (A), the Secretary shall finalize the updated guidance. (d) Report on coding, coverage, and payment processes under Medicare for new medical products (1) In general Not later than 12 months after the date of enactment of this Act, the Secretary of Health and Human Services shall publish a report on the internet website of the Department of Health and Human Services regarding processes under the Medicare program under title XVIII of the Social Security Act ( 42 U.S.C. 1395 (A) A description of challenges in the coding, coverage, and payment processes under the Medicare program for medical products described in such paragraph. (B) Recommendations to— (i) incorporate patient experience data (such as the impact of a disease or condition on the lives of patients and patient treatment preferences) into the coverage and payment processes within the Centers for Medicare & Medicaid Services; (ii) decrease the length of time to make national and local coverage determinations under the Medicare program (as those terms are defined in subparagraph (A) and (B), respectively, of section 1862(l)(6) of the Social Security Act ( 42 U.S.C. 1395y(l)(6) (iii) streamline the coverage process under the Medicare program and incorporate input from relevant stakeholders into such coverage determinations; and (iv) identify potential mechanisms to incorporate novel payment designs similar to those in development in commercial insurance plans and State plans under title XIX of the Social Security Act ( 42 U.S.C. 1396r (2) Medical products described For purposes of paragraph (1), a medical product described in this paragraph is a medical product, including a drug, biological (including gene and cell therapy and gene editing), or medical device, that has been designated as a breakthrough therapy under section 506(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356(a) 21 U.S.C. 360e–3 21 U.S.C. 356(g) II Education provisions 4501. Short title This title may be cited as the COVID-19 Pandemic Education Relief Act of 2020 4502. Definitions (a) Definitions In this title: (1) Qualifying emergency The term qualifying emergency (A) a public health emergency declared by the Secretary of Health and Human Services pursuant to section 319 of the Public Health Service Act ( 42 U.S.C. 247d (B) an event for which the President declared a major disaster or an emergency under section 401 or 501, respectively, of the Robert T. Stafford Disaster Relief and Emergency Assistance Act ( 42 U.S.C. 5170 (C) a national emergency declared by the President under section 201 of the National Emergencies Act ( 50 U.S.C. 1601 (2) Institution of higher education The term institution of higher education 20 U.S.C. 1002 (3) Secretary The term Secretary 4503. Campus-based aid waivers (a) Waiver of non-federal share requirement Notwithstanding sections 413C(a)(2) and 443(b)(5) of the Higher Education Act of 1965 ( 20 U.S.C. 1070b–2(a)(2) 20 U.S.C. 1070b (b) Authority to reallocate Notwithstanding sections 413D, 442, and 488 of the Higher Education Act of 1965 ( 20 U.S.C. 1070b–3 4504. Use of supplemental educational opportunity grants for emergency aid (a) In general Notwithstanding section 413B of the Higher Education Act of 1965 ( 20 U.S.C. 1070b–1 20 U.S.C. 1070b (b) Determinations In determining eligibility for and awarding emergency financial aid grants under this section, an institution of higher education may— (1) waive the amount of need calculation under section 471 of the Higher Education Act of 1965 ( 20 U.S.C. 1087kk (2) allow for a student affected by a qualifying emergency to receive funds in an amount that is not more than the maximum Federal Pell Grant for the applicable award year; and (3) utilize a contract with a scholarship-granting organization designated for the sole purpose of accepting applications from or disbursing funds to students enrolled in the institution of higher education, if such scholarship-granting organization disburses the full allocated amount provided to the institution of higher education to the recipients. (c) Special rule Any emergency financial aid grants to students under this section shall not be treated as other financial assistance for the purposes of section 471 of the Higher Education Act of 1965 ( 20 U.S.C. 1087kk 4505. Federal work-study during a qualifying emergency (a) In general In the event of a qualifying emergency, an institution of higher education participating in the program under part C of title IV of the Higher Education Act of 1965 ( 20 U.S.C. 1087–51 (1) Payments may be made under such part to affected work-study students in an amount equal to or less than the amount of wages such students would have been paid under such part had the students been able to complete the work obligation necessary to receive work study funds, as a one time grant or as multiple payments. (2) Payments shall not be made to any student who was not eligible for work study or was not completing the work obligation necessary to receive work study funds under such part prior to the occurrence of the qualifying emergency. (3) Any payments made to affected work-study students under this subsection shall meet the matching requirements of section 443 of the Higher Education Act of 1965 ( 20 U.S.C. 1087–53 (b) Definition of affected work-study student In this section, the term affected work-study student 20 U.S.C. 1087–51 (1) received a work-study award under section 443 of the Higher Education Act of 1965 ( 20 U.S.C. 1087–53 (2) earned Federal work-study wages from such eligible institution for such academic year; and (3) was prevented from fulfilling the student’s work-study obligation for all or part of such academic year due to such qualifying emergency. 4506. Adjustment of subsidized loan usage limits Notwithstanding section 455(q)(3) of the Higher Education Act of 1965 ( 20 U.S.C. 1087e(q)(3) 20 U.S.C. 1087a 4507. Exclusion from Federal Pell Grant duration limit The Secretary shall exclude from a student’s Federal Pell Grant duration limit under section 401(c)(5) of the Higher Education Act of 1965 ( 2 U.S.C. 1070a(c)(5) 4508. Institutional refunds and Federal student loan flexibility (a) Institutional waiver The Secretary may waive the institutional requirement in section 484B of the Higher Education Act of 1965 ( 20 U.S.C. 1091b 20 U.S.C. 1070 (b) Student waiver The Secretary may waive the amounts that students are required to return in section 484B of the Higher Education Act of 1965 ( 20 U.S.C. 1091b (c) Canceling loan obligation Notwithstanding any other provision of the Higher Education Act of 1965 ( 20 U.S.C. 1001 (d) Approved leave of absence Notwithstanding any other provision of law, for purposes of receiving assistance under title IV of the Higher Education Act of 1965 ( 20 U.S.C. 1070 4509. Satisfactory progress Notwithstanding section 484 of the Higher Education Act of 1965 ( 20 U.S.C. 1091 20 U.S.C. 1070 4510. Continuing education at affected foreign institutions (a) In general Notwithstanding section 481(b) of the Higher Education Act of 1965 ( 20 U.S.C. 1088(b) 20 U.S.C. 1070 (b) Eligibility An otherwise eligible program that is offered in whole or in part through distance education by a foreign institution between March 1, 2020, and the date of enactment of this Act shall be deemed eligible for the purposes of part D of title IV of the Higher Education Act of 1965 ( 20 U.S.C. 1087a 20 U.S.C. 1070 (c) Report Not later than 180 days after the date of enactment of this Act, and every 180 days thereafter for the duration of the qualifying emergency and the following payment period, the Secretary shall submit to the authorizing committees (as defined in section 103 of the Higher Education Act of 1965 ( 20 U.S.C. 1003 (d) Written arrangements (1) In general Notwithstanding section 102 of the Higher Education Act of 1965 ( 20 U.S.C. 1002 20 U.S.C. 1087a (2) Form of arrangements (A) Public or other nonprofit institutions A foreign institution that is a public or other nonprofit institution may enter into a written arrangement under subsection (a) only with an institution of higher education described in section 101 of such Act ( 20 U.S.C. 1001 (B) Other institutions A foreign institution that is a graduate medical school, nursing school, or a veterinary school and that is not a public or other nonprofit institution may enter into a written arrangement under subsection (a) with an institution of higher education described in section 101 or section 102 of such Act ( 20 U.S.C. 1001 (3) Report use Not later than June 30, 2020, an institution of higher that uses the authority described in paragraph (2) shall report such use to the Secretary. (4) Report from the secretary Not later than 180 days after the date of enactment of this Act, and every 180 days thereafter for the duration of the qualifying emergency and the following payment period, the Secretary shall submit to the authorizing committees (as defined in section 103 of the Higher Education Act of 1965 ( 20 U.S.C. 1003 4511. National emergency educational waivers (a) In general Notwithstanding any other provision of law, the Secretary of Education may waive any statutory or regulatory provision described under subparagraphs (A) through (C) of subsection (b)(1) if the Secretary determines that such a waiver is necessary and appropriate due to the emergency involving Federal primary responsibility determined to exist by the President under the section 501(b) of the Robert T. Stafford Disaster Relief and Emergency Assistance Act ( 42 U.S.C. 5191(b) (b) Applicable provisions of law (1) In general The Secretary of Education may waive any statutory or regulatory requirement (such as those requirements related to assessments, accountability, allocation of funds, and reporting), for which a waiver request is submitted under subsection (c), if the Secretary determines that such a waiver is necessary and appropriate as described in subsection (a), under the following provisions of law: (A) The Elementary and Secondary Education Act of 1965 ( 20 U.S.C. 6301 (B) The Carl D. Perkins Career and Technical Education Act of 2006 ( 20 U.S.C. 2301 (C) The Higher Education Act of 1965 ( 20 U.S.C. 1001 (2) Limitation The Secretary of Education shall not waive under this section any statutory or regulatory requirements relating to applicable civil rights laws. (c) Requests for waivers (1) In general In addition to any provision waived by the Secretary under subsection (a), a State, State educational agency, local educational agency, Indian tribe, or institution of higher education that desires a waiver from any statutory or regulatory provision described under subparagraphs (A) through (C) of subsection (b)(1) that the Secretary has not already waived in accordance with subsection (a), may submit a waiver request to the Secretary in accordance with this subsection. (2) Requests submitted A request for a waiver under this subsection shall— (A) identify the Federal programs affected by the requested waiver; (B) describe which Federal statutory or regulatory requirements are to be waived; and (C) describe how the emergency involving Federal primary responsibility determined to exist by the President under the section 501(b) of the Robert T. Stafford Disaster Relief and Emergency Assistance Act ( 42 U.S.C. 5191(b) (3) Secretary approval (A) In general Except as provided under subparagraph (B), the Secretary of Education shall approve or disapprove a waiver request submitted under paragraph (1) not more than 15 days after the date on which such request is submitted. (B) Exceptions The Secretary of Education may disapprove a waiver request submitted under paragraph (1), only if the Secretary determines that— (i) the waiver request does not meet the requirements of this section; (ii) the waiver is not permitted pursuant to subsection (b)(2); or (iii) the description required under paragraph (2)(C) provides insufficient information to demonstrate that the waiving of such requirements is necessary or appropriate consistent with subsection (a). (4) Duration (A) In general Except as provided in paragraph (B), a waiver approved by the Secretary of Education under this subsection may be for a period not to exceed 1 academic year. (B) Extension The Secretary of Education may extend the period described under subparagraph (A) if the State, State educational agency, local educational agency, Indian tribe, or institution of higher education demonstrates to the Secretary that extending the waiving of such requirements is necessary and appropriate consistent with subsection (a). (d) Reporting and publication (1) Notifying congress Not later than 7 days after granting a waiver under this section, the Secretary of Education shall notify the Committee on Health, Education, Labor, and Pensions of the Senate, the Committee on Appropriations of the Senate, the Committee on Education and Labor of the House of Representatives, and the Committee on Appropriations of the House of Representatives of such waiver. (2) Publication Not later than 30 days after granting a waiver under this section, the Secretary of Education shall publish a notice of the Secretary’s decision in the Federal Register and on the website of the Department of Education. (3) IDEA report Not later than 30 days after the date of enactment of this Act, the Secretary of Education shall prepare and submit a report to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate, and the Committee on Education and Labor and the Committee on Appropriations of the House of Representatives, with recommendations on any additional waivers the Secretary believes are necessary to be enacted into law under the Individuals with Disabilities Education Act ( 20 U.S.C. 1401 29 U.S.C. 701 42 U.S.C. 5191(b) 4512. HBCU Capital financing (a) Deferment period (1) In general Notwithstanding any provision of title III of the Higher Education Act of 1965 ( 20 U.S.C. 1051 20 U.S.C. 1066 (2) Terms During the deferment period granted under this subsection— (A) the institution shall not be required to pay any periodic installment of principal required under the loan agreement for such loan; and (B) the Secretary shall make principal payments otherwise due under the loan agreement. (3) Closing At the closing of a loan deferred under this subsection, terms shall be set under which the institution shall be required to repay the Secretary for the payments of principal made by the Secretary during the deferment, on a schedule that begins upon repayment to the lender in full on the loan agreement. (b) Termination date (1) In general Except as provided in paragraph (2), the authority provided under this section to grant a loan deferment under subsection (a), shall terminate on the date that is the end of the qualifying emergency. (2) Duration Any provision of a loan agreement or insurance agreement modified or waived by the authority under this section shall remain so modified or waived for the duration of the period covered by the loan agreement or insurance agreement. (c) Report Not later than 180 days after the date of enactment of this Act, and every 180 days thereafter during the period beginning on the first day of the qualifying emergency and ending on September 30 of the fiscal year following the end of the qualifying emergency, the Secretary shall submit to the authorizing committees (as defined in section 103 of the Higher Education Act of 1965 ( 20 U.S.C. 1003 4513. Temporary relief for federal student loan borrowers (a) In general The Secretary shall suspend all payments due for loans made under part D of title IV of the Higher Education Act of 1965 ( 20 U.S.C. 1087a (b) No accrual of interest Notwithstanding any other provision of the Higher Education Act of 1965 ( 20 U.S.C. 1001 (c) Consideration of payments The Secretary shall deem each month for which a loan payment was suspended under this section as if the borrower of the loan had made a payment for the purpose of any loan forgiveness program authorized under part D of title IV of the Higher Education Act of 1965 ( 20 U.S.C. 1087a (d) Extension The Secretary may extend the period of suspension described under subsection (a) for an additional 3 months. 4514. Provisions related to the Corporation for National and Community Service (a) Accrual of service hours (1) Accrual through other service hours (A) In general Notwithstanding any other provision of the Domestic Volunteer Service Act of 1973 ( 42 U.S.C. 4950 42 U.S.C. 12501 (B) Affected individuals Subparagraph (A) shall apply to any individual serving in a position eligible for an educational award under subtitle D of title I of the National and Community Service Act of 1990 ( 42 U.S.C. 12601 (i) who is performing limited service due to COVID-19; or (ii) whose position has been suspended or placed on hold due to COVID-19. (2) Provisions in case of early exit In any case where an individual serving in a position eligible for an educational award under subtitle D of title I of the National and Community Service Act of 1990 ( 42 U.S.C. 12601 (A) deem such individual as having met the requirements of the position; and (B) award the individual the full value of the educational award under such subtitle for which the individual would otherwise have been eligible. (b) Availability of funds Notwithstanding any other provision of law, all funds made available to the Corporation for National and Community Service under any Act, including the amounts appropriated to the Corporation under the headings Operating Expenses Salaries and Expenses Office of the Inspector General Corporation for National and Community Service Public Law 116–94 (c) No required return of grant funds Notwithstanding section 129(l)(3)(A)(i) of the National and Community Service Act of 1990 ( 42 U.S.C. 12581(l)(3)(A)(i) (d) Extension of terms and age limits Notwithstanding any other provision of law, the Corporation for National and Community Service may extend the term of service (for a period not to exceed the 1-year period immediately following the end of the national emergency) or waive any upper age limit (except in no case shall the maximum age exceed 26 years of age) for national service programs carried out by the National Civilian Community Corps under subtitle E of title I of the National and Community Service Act of 1990 ( 42 U.S.C. 12611 (1) addressing disruptions due to COVID-19; and (2) minimizing the difficulty in returning to full operation due to COVID-19 on such programs and participants. 4515. Workforce response activities (a) Administrative costs Of the total amount allocated to a local area under section 128(b) of the Workforce Innovation and Opportunity Act ( 29 U.S.C. 3163(b) 29 U.S.C. 3173(b) 29 U.S.C. 3151 (b) Rapid response activities (1) Statewide rapid response Of the funds available for program year 2019 for statewide activities under section 128(a) of the Workforce Innovation and Opportunity Act ( 29 U.S.C. 3163(a) 29 U.S.C. 3174(a)(2)(A) (2) Local boards Of the funds available to a Governor under section 133(a)(2) of such Act ( 29 U.S.C. 3173(a)(2) (c) Definitions In this section: (1) Coronavirus The term coronavirus Public Law 116–123 (2) COVID-19 national emergency The term COVID-19 national emergency 50 U.S.C. 1601 (3) WIOA terms Except as otherwise provided, the terms in this section have the meanings given the terms in section 3 of the Workforce Innovation and Opportunity Act ( 29 U.S.C. 3102 4516. Technical amendments (a) In general (1) Section 6103(a)(3) Public Law 116–91 (13), (16) (13)(A), (13)(B), (13)(C), (13)(D)(i), (16) (2) Section 6103(p)(3)(A) of such Code, as so amended, is further amended by striking (12), (12), (13)(A), (13)(B), (13)(C), (13)(D)(i) (3) Section 6103(p)(4) of such Code, as so amended, is further amended by striking (13) or (16) (13), or (16) (4) Section 6103(p)(4) of such Code, as so amended and as amended by paragraph (3), is further amended by striking (13) (13)(A), (13)(B), (13)(C), (13)(D)(i) (5) Section 6103(l)(13)(C)(ii) of such Code, as added by the FUTURE Act ( Public Law 116–91 section 236A(e)(4) section 263A(e)(4) (b) Effective date The amendments made by this section shall apply as if included in the enactment of the FUTURE Act ( Public Law 116–91 III Labor provisions 4601. Limitation on paid leave Section 110(b)(2)(B) of the Family and Medical Leave Act of 1993 (as added by the Emergency Family and Medical Leave Expansion Act) is amended by striking clause (ii) and inserting the following: (ii) Limitation An employer shall not be required to pay more than $200 per day and $10,000 in the aggregate for each employee for paid leave under this section. . 4602. Emergency Paid Sick Leave Act Limitation Section 5102 of the Emergency Paid Sick Leave Act (division E of the Families First Coronavirus Response Act) is amended by adding at the end the following: (f) Limitations (1) In General An employer shall not be required to pay more than either— (A) $511 per day and $5,110 in the aggregate for each employee, when the employee is taking leave for a reason described in paragraph (1), (2), or (3) of section 5102(a); or (B) $200 per day and $2,000 in the aggregate for each employee, when the employee is taking leave for a reason described in paragraph (4), (5), or (6) of section 5102(a). (2) Expiration of requirement An employer's requirement to provide paid leave with respect to a specific employee shall expire at the earlier of— (A) the time when the employer has paid that employee for paid leave under this section for an equivalent of 80 hours of work; or (B) upon the employee's return to work after taking paid leave under this section. . 4603. Regulatory Authorities under the Emergency Paid Sick Leave Act Section 5111(2) of the Emergency Paid Sick Leave Act (division E of the Families First Coronavirus Response Act) is amended by striking section 5102(a)(5) paragraphs (4) and (5) of section 5102(a)(5) 4604. Unemployment insurance Section 903(h)(2)(B) of the Social Security Act ( 42 U.S.C. 1103(h)(2)(B) (B) The State ensures that applications for unemployment compensation, and assistance with the application process, are accessible in person, by phone, or online. . 4605. OMB Waiver of Paid Family and Paid Sick Leave (a) Family and Medical Leave Act of 1993 Section 110(a) of title I of the Family and Medical Leave Act of 1993 ( 29 U.S.C. 2611 (4) The Director of the Office of Management and Budget shall have the authority to exclude for good cause from the requirements under subsection (b) certain employers of the United States Government with respect to certain categories of Executive Branch employees. . (b) Emergency Paid Sick Leave Act The Emergency Paid Sick Leave Act (division E of the Families First Coronavirus Response Act) is amended by adding at the end the following new section: 5112. Authority to exclude certain employees The Director of the Office of Management and Budget shall have the authority to exclude for good cause from the definition of employee under section 5110(1) certain employees described in subparagraphs (E) and (F) of such section, including by exempting certain United States Government employers covered by section 5110(2)(A)(i)(V) from the requirements of this title with respect to certain categories of Executive Branch employees. . 4606. Paid leave for rehired employees Section 110(a)(1)(A) of the Family and Medical Leave Act of 1993, as added by section 3102 of the Emergency Family and Medical Leave Expansion Act, is amended to read as follows: (A) Eligible employee (i) In general In lieu of the definition in sections 101(2)(A) and 101(2)(B)(ii), the term eligible employee (ii) Rule regarding rehired employees For purposes of clause (i), the term employed for at least 30 calendar days . 4607. Advance refunding of credits (a) Payroll credit for required paid sick leave Section 7001 of division G of the Families First Coronavirus Response Act is amended by inserting after subsection (g) the following new subsection: (h) Treatment of deposits The Secretary of the Treasury (or the Secretary's delegate) shall waive any penalty under section 6656 . (b) Credit for sick leave for certain self-employed individuals Section 7002 of division G of the Families First Coronavirus Response Act is amended by inserting after subsection (g) the following new subsection: (h) Advancing credit The Secretary of the Treasury (or the Secretary's delegate) shall issue such forms and instructions as are necessary— (1) to allow the advance payment of the credit under subsection (a), subject to the limitations provided in this section, based on such information as the Secretary shall require, and (2) to provide for the reconciliation of such advance payment with the amount advanced at the time of filing the return of tax for the taxable year. . (c) Payroll credit for required paid family leave Section 7003 of division G of the Families First Coronavirus Response Act is amended by inserting after subsection (g) the following new subsection: (h) Treatment of deposits The Secretary of the Treasury (or the Secretary's delegate) shall waive any penalty under section 6656 . (d) Credit for family leave for certain self-employed individuals Section 7004 of division G of the Families First Coronavirus Response Act is amended by inserting after subsection (e) the following new subsection: (f) Advancing credit The Secretary of the Treasury (or the Secretary's delegate) shall issue such forms and instructions as are necessary— (1) to allow the advance payment of the credit under subsection (a), subject to the limitations provided in this section, based on such information as the Secretary shall require, and (2) to provide for the reconciliation of such advance payment with the amount advanced at the time of filing the return of tax for the taxable year. . E Temporary Permit Use to Guarantee Money Market Mutual Funds 5001. Non-applicability of restrictions on ESF during national emergency Section 131 of the Emergency Economic Stabilization Act of 2008 ( 12 U.S.C. 5236 50 U.S.C. 1601 F Budgetary provisions 6001. Emergency designation (a) In general The amounts provided under this Act are designated as an emergency requirement pursuant to section 4(g) of the Statutory Pay-As-You-Go Act of 2010 ( 2 U.S.C. 933(g) (b) Designation in senate In the Senate, this Act is designated as an emergency requirement pursuant to section 4112(a) of H. Con. Res. 71 (115th Congress), the concurrent resolution on the budget for fiscal year 2018.

Summary: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act This bill addresses economic impacts of, and otherwise responds to, the COVID-19 (coronavirus) outbreak. The bill authorizes emergency loans to distressed businesses, including air carriers, and suspends certain aviation excise taxes. With respect to small businesses, the bill establishes, and provides funding for, forgivable bridge loans; and provides additional funding for grants and technical assistance. The bill also provides funding for $1,200 tax rebates to individuals, with additional $500 payments per qualifying child. The rebate begins phasing out when incomes exceed $75,000 (or $150,000 for joint filers). The bill establishes limits on requirements for employers to provide paid leave. With respect to taxes, the bill establishes special rules for certain tax-favored withdrawals from retirement plans; delays due dates for employer payroll taxes and estimated tax payments for corporations; and revises other provisions, including those related to losses, charitable deductions, and business interest. With respect to health care, the bill provides additional funding for the prevention, diagnosis, and treatment of COVID-19; limits liability for volunteer health care professionals; prioritizes Food and Drug Administration (FDA) review of certain drugs; allows emergency use of certain diagnostic tests that are not approved by the FDA; expands health-insurance coverage for diagnostic testing and requires coverage for preventative services and vaccines; revises other provisions, including those regarding the medical supply chain, the national stockpile, the health care workforce, the Healthy Start program, telehealth services, nutrition services, Medicare, and Medicaid. With respect to education, the bill temporarily suspends payments for federal student loans; and  otherwise revises provisions related to campus-based aid, supplemental educational-opportunity grants, federal work-study, subsidized loans, Pell grants, and foreign institutions. The bill also authorizes the Department of the Treasury to temporarily guarantee money-market funds.